Document:

exv4w1

 

Exhibit 4.1

EXECUTION VERSION

CERTIFICATE OF DESIGNATION,

PREFERENCES AND RIGHTS

of

SERIES B CONVERTIBLE PREFERRED STOCK

of

REMOTE DYNAMICS, INC.

(Pursuant to Section 151 of the

Delaware General Corporation Law)

     Remote Dynamics, Inc., a corporation organized and existing under the laws of the State of
Delaware (the “Corporation”), hereby certifies that the Board of Directors of the Corporation (the
“Board of Directors” or the “Board”), pursuant to authority of the Board of Directors as required
by Section 151 of the Delaware General Corporation Law, and in accordance with the provisions of
its Certificate of Incorporation and Bylaws, each as amended and restated through the date hereof,
has and hereby authorizes a series of the Corporation’s previously authorized Preferred Stock, par
value $.01 per share (the “Preferred Stock”), and hereby states the designation and number of
shares, and fixes the relative rights, preferences, privileges, powers and restrictions thereof, as
follows:

I. DESIGNATION AND AMOUNT

     The designation of this series, which consists of Six Hundred Fifty (650) shares of Preferred
Stock, is the Series B Convertible Preferred Stock (the “Series B Preferred Stock”) and the face
amount shall be Ten Thousand Dollars ($10,000.00) per share (the “Face Amount”).

II. CERTAIN DEFINITIONS

     For purposes of this Certificate of Designation, in addition to the other terms defined
herein, the following terms shall have the following meanings:

     A. “business day” means any day, other than a Saturday or Sunday or a day on which banking
institutions in the State of New York are authorized or obligated by law, regulation or executive
order to close.

     B. “Change of Control” means (i) any sale, transfer or other disposition of all or
substantially all of the assets of the Corporation, (ii) the adoption of a plan relating to the
liquidation or dissolution of the Corporation, (iii) any consolidation or merger of the Corporation
with any other entity (other than a merger in which the Corporation is the surviving or continuing entity and
its

 

 

capital stock is unchanged), (iv) any share exchange or other transaction pursuant to which all
of the outstanding shares of Common Stock are converted into other securities or property, (v) any
reclassification or change of the outstanding shares of Common Stock (other than a change in par
value, or from par value to no par value, or from no par value to par value, or as a result of a
subdivision or combination), (vi) any sale or issuance, in one transaction or a series of related
transactions, by the Corporation or any of its stockholders of any Common Stock or Convertible
Securities (as defined in Article X.D, below) to any person such that, following the consummation
of such transaction(s), such person (together with its affiliates) would own or have the right to
acquire greater than fifty percent (50%) of the outstanding shares of Common Stock (calculated on a
fully-diluted basis assuming the conversion or exercise of all Convertible Securities), or to elect
a majority of the Board, or (vii) the first day on which the continuing directors (i.e., the
current members of the Board, or those members who are subsequently elected with the approval of a
majority of the then current members of the Board) cease to represent at least a majority of the
members of the Board then serving.

     C. “Closing Sales Price” means, for any security as of any date, the last sales price of such
security on the principal trading market where such security is listed or traded as reported by
Bloomberg Financial Markets (or a comparable reporting service of national reputation selected by
the Corporation and reasonably acceptable to the Series B Majority Holders if Bloomberg Financial
Markets is not then reporting closing sales prices of such security) (collectively, “Bloomberg”),
or if the foregoing does not apply, the last reported sales price of such security on a national
exchange or in the over-the-counter market on the electronic bulletin board for such security as
reported by Bloomberg, or, if no such price is reported for such security by Bloomberg, the average
of the bid prices of all market makers for such security as reported in the “pink sheets” by the
National Quotation Bureau, Inc., in each case for such date or, if such date was not a trading day
for such security, on the next preceding date which was a trading day. If the Closing Sales Price
cannot be calculated for such security as of either of such dates on any of the foregoing bases,
the Closing Sales Price of such security on such date shall be the fair market value as reasonably
determined by an investment banking firm selected by the Corporation and reasonably acceptable to
the Series B Majority Holders, with the costs of such appraisal to be borne by the Corporation.

     D. “Conversion Date” means, for any Optional Conversion (as defined in Article IV.A below),
the date specified in the notice of conversion in the form attached hereto (the “Notice of
Conversion”), so long as such day is a trading day and a copy of the Notice of Conversion is faxed
(or delivered by other means resulting in notice) to the Corporation before 4:00 p.m., New York
City time, on the Conversion Date indicated in the Notice of Conversion; provided, however, that if
the Notice of Conversion is not so faxed or otherwise delivered before such time, then the
Conversion Date shall be the next trading day after the date the holder faxes or otherwise delivers
the Notice of Conversion to the Corporation.

     E. “Conversion Price” means $1.55 per share; provided, however, that the Conversion Price
shall be subject to adjustment as provided herein.

     F. “Default Cure Date” means, as applicable, (i) with respect to a Conversion Default
described in clause (i) of Article VI.A, the date the Corporation effects the conversion of the
full number of shares of Series B Preferred Stock, (ii) with respect to a Conversion Default
described in

- 2 -

 

clause (ii) of Article VI.A, the date the Corporation issues freely tradable shares of
Common Stock in satisfaction of all conversions of Series B Preferred Stock in accordance with
Article IV, or (iii) with respect to either type of a Conversion Default, the date on which the
Corporation redeems shares of Series B Preferred Stock held by such holder pursuant to Article VI.A
and/or Article VII.A.

          “Dilutive Issuance” means the issuance or sale, or such other action that is deemed by this
definition to constitute an issuance or sale, by the Corporation of any shares of Common Stock for
no consideration or for a consideration per share less than the Conversion Price in effect on the
date of issuance or sale (or deemed issuance or sale). For the purposes of determining whether
shares of Common Stock are issued or sold for no consideration or for a consideration per share
less than the Conversion Price in effect on the date of issuance or sale (or deemed issuance or
sale), the following shall be applicable:

               (i) Issuance of Purchase Rights. If the Corporation issues or sells any Purchase Rights
(defined below), whether or not immediately exercisable, and the price per share for which Common
Stock is issuable upon the exercise of such Purchase Rights (and the price of any conversion of
Convertible Securities, if applicable) is less than the Conversion Price in effect on the date of
issuance or sale of such Purchase Rights, then the maximum total number of shares of Common Stock
issuable upon the exercise of all such Purchase Rights (assuming full conversion, exercise or
exchange of Convertible Securities, if applicable) shall, as of the date of the issuance or sale of
such Purchase Rights, be deemed to be outstanding and to have been issued and sold by the
Corporation for such price per share. For purposes of the preceding sentence, the “price per share
for which Common Stock is issuable upon the exercise of such Purchase Rights” shall be determined
by dividing (A) the total amount, if any, received or receivable by the Corporation as
consideration for the issuance or sale of all such Purchase Rights, plus the minimum aggregate
amount of additional consideration, if any, payable to the Corporation upon the exercise of all
such Purchase Rights, plus, in the case of Convertible Securities issuable upon the exercise of
such Purchase Rights, the minimum aggregate amount of additional consideration payable upon the
conversion, exercise or exchange thereof (determined in accordance with the calculation method set
forth in subparagraph (iii) of this definition), by (B) the maximum total number of shares of
Common Stock issuable upon the exercise of all such Purchase Rights (assuming full conversion,
exercise or exchange of Convertible Securities, if applicable).

               (ii) Issuance of Convertible Securities. If the Corporation issues or sells any Convertible
Securities (defined below), whether or not immediately convertible, exercisable or exchangeable,
and the price per share for which Common Stock is issuable upon such conversion, exercise or
exchange is less than the Conversion Price in effect on the date of issuance or sale of such
Convertible Securities, then the maximum total number of shares of Common Stock issuable upon the
conversion, exercise or exchange of all such Convertible Securities shall, as of the date of the
issuance or sale of such Convertible Securities, be deemed to be outstanding and to have been
issued and sold by the Corporation for such price per share. For the purposes of the preceding
sentence, the “price per share for which Common Stock is issuable upon such conversion, exercise or
exchange” shall be determined by dividing (A) the total amount, if any, received or receivable by
the Corporation as consideration for the issuance or sale of all such Convertible Securities, plus
the minimum aggregate amount of additional consideration, if any, payable to the Corporation upon
the conversion, exercise
or exchange thereof (determined in accordance with the calculation method set

- 3 -

 

forth in
subparagraph (iii) of this definition), by (B) the maximum total number of shares of Common Stock
issuable upon the exercise, conversion or exchange of all such Convertible Securities.

               (iii) Calculation of Consideration Received. If any Common Stock, Purchase Rights or
Convertible Securities are issued or sold for cash, the consideration received therefor will be the
amount received by the Corporation therefor, after deduction of all underwriting discounts or
allowances in connection with such issuance, grant or sale. In case any Common Stock, Purchase
Rights or Convertible Securities are issued or sold for a consideration part or all of which shall
be other than cash, including in the case of a strategic or similar arrangement in which the other
entity will provide services to the Corporation, purchase services from the Corporation or
otherwise provide intangible consideration to the Corporation, the amount of the consideration
other than cash received by the Corporation (including the net present value of the consideration
expected by the Corporation for the provided or purchased services) shall be the fair market value
of such consideration, except where such consideration consists of securities, in which case the
amount of consideration received by the Corporation will be the Closing Sales Price thereof as of
the date of receipt. In case any Common Stock, Purchase Rights or Convertible Securities are
issued in connection with any merger or consolidation in which the Corporation is the surviving
corporation, the amount of consideration therefor will be deemed to be the fair market value of
such portion of the net assets and business of the non-surviving corporation as is attributable to
such Common Stock, Purchase Rights or Convertible Securities, as the case may be. Notwithstanding
anything else herein to the contrary, if Common Stock, Purchase Rights or Convertible Securities
are issued or sold in conjunction with each other as part of a single transaction or in a series of
related transactions, the Holder may elect to determine the amount of consideration deemed to be
received by the Corporation therefor by deducting the fair value of any type of securities (the
“Disregarded Securities”) issued or sold in such transaction or series of transactions. For
example, if the Corporation were to issue convertible notes having a face value of $1,000,000 and
warrants to purchase shares of Common Stock at an exercise price equal to the market price of the
Common Stock on the date of issuance of such warrants in exchange for $1,000,000 of consideration,
the fair value of the warrants would be subtracted from the $1,000,000 of consideration received by
the Corporation for the purposes of determining whether the shares of Common Stock issuable upon
conversion of the convertible notes shall be deemed to be issued at a price per share below the
Conversion Price then in effect. The Corporation shall calculate, using standard commercial
valuation methods appropriate for valuing such assets, the fair market value of any consideration
other than cash or securities; provided, however, that if the Holder does not agree to such fair
market value calculation within three business days after receipt thereof from the Corporation,
then such fair market value shall be determined in good faith by an investment banker or other
appropriate expert of national reputation selected by the Corporation and reasonably acceptable to
the Holder, with the costs of such appraisal to be borne by the Corporation.

               (iv) Excluded Issuances. Notwithstanding the foregoing, none of the following issuances shall
be deemed to be “Dilutive Issuances”: (i) the issuance of Common Stock upon the exercise or
conversion of any Convertible Securities or Purchase Rights outstanding on the Issuance Date and
disclosed in Section 3(c) of the Disclosure Schedule to the Securities Purchase Agreement between
the Corporation and the purchaser named therein (the “Series B Securities Purchase Agreement”) in
accordance with the terms of such Convertible Securities and Purchase

- 4 -

 

Rights as of such date; (ii) the grant of options to purchase Common Stock, with exercise
prices not less than the market price of the Common Stock on the date of grant, which are issued to
employees, officers, directors or consultants of the Corporation for the primary purpose of
soliciting or retaining their employment or service pursuant to an equity compensation plan of the
Corporation in effect as of the date hereof, and the issuance of Common Stock upon the exercise
thereof; (iii) the conversion of the Series B Preferred Stock or the sale and issuance of the
Warrants or their exercise for shares of Common Stock, (iv) the issuance of securities in
connection with strategic business partnerships or joint ventures, the primary purpose of which, in
the reasonable judgment of the Board of Directors, is not to raise additional capital; (v) the
issuance of securities in connection with a bona fide public offering at an offering price per
share (prior to underwriter’s commissions and discounts) of not less than the Conversion Price (as
adjusted pursuant to the terms hereof) that is underwritten by a nationally recognized underwriting
firm and results in net proceeds to the Corporation of at least twenty-five million dollars
($25,000,000); (vi) any issuance of securities as to which the Series B Majority Holders shall have
executed a written waiver of its rights hereunder; (vii) the issuance of Common Stock pursuant to,
and upon the exercise of options granted under, the Company’s 2005 Incentive Plan (but only up to
such amount as provided for in Section 3(c) of the Disclosure Schedule to the Series B Securities
Purchase Agreement); or (viii) the issuance of Common Stock pursuant to the Company’s Third Amended
Joint Plan of Reorganization (but only up to such amount as provided for in Section 3(c) of the
Disclosure Schedule to the Series B Securities Purchase Agreement).

     G. “Issuance Date” means the date of the closing under the Series B Securities Purchase
Agreement, pursuant to which the Corporation issues, and such purchasers purchase, shares of Series
B Preferred Stock upon the terms and conditions stated therein.

     H. “Registration Rights Agreement” means the Registration Rights Agreement, to be dated as of
the Issuance Date, by and among the Corporation and the initial holders of Series B Preferred
Stock.

     I. “Series B Majority Holders” means the holders of a majority of the then outstanding shares
of Series B Preferred Stock.

     J. “trading day” means any day on which the principal United States securities exchange or
trading market where the Common Stock is then listed or traded, is open for trading.

     K. “Warrants” means (i) the warrants to acquire shares of Common Stock issued to the purchaser
of the Company’s Series A Preferred Stock in connection with that Securities Purchase Agreement
dated October 1, 2004 (the “Series A Securities Purchase Agreement”), (ii) the warrants to acquire
shares of Common Stock to be issued to the purchaser(s) of Series B Preferred Stock in connection
with the issuance thereof pursuant to the Series B Securities Purchase Agreement, and (iii) the
warrants to be issued by the Corporation to the holder of the promissory note (the “Note”) issued
pursuant to the Series B Securities Purchase Agreement in consideration of the exchange of such
Note in accordance with the terms thereof.

- 5 -

 

III. DIVIDENDS

     Dividends (the “Dividends”) shall be payable cumulatively, at the rate of eight percent (8%)
per annum (calculated on the basis of a 365-day year), which rate shall automatically decrease
to three percent (3%) per annum on September 1, 2006, (a) upon any conversion for each share of
Series B Preferred Stock, and (b) as to each outstanding share of Series B Preferred Stock, on
August 31, November 30, February 28 and May 31 of each year, beginning August 31, 2005 and ending
on the earlier of (1) August 31, 2008 and (2) the date such share of Series B Preferred Stock is
fully converted or fully redeemed. Payment of the Dividend shall be made at the election of the
holder of each share of Series B Preferred Stock (i) in cash, or (ii) in such number of shares of
Series B Preferred Stock determined by dividing the amount of the Dividend by the Face Amount.

IV. CONVERSION

     A. Conversion at the Option of the Holder. Subject to the limitations on conversions
contained in Article XIV, each holder of shares of Series B Preferred Stock may, at any time and
from time to time, convert (an “Optional Conversion”) each of its shares of Series B Preferred
Stock into a number of fully paid and nonassessable shares of Common Stock determined in accordance
with the following formula:

Face Amount

Conversion Price

     B. Mechanics of Conversion. In order to effect an Optional Conversion, a holder
shall: (x) fax (or otherwise deliver) a copy of the fully executed Notice of Conversion to the
Corporation (Attention: Secretary) and (y) surrender or cause to be surrendered the original
certificates representing the Series B Preferred Stock being converted (the “Preferred Stock
Certificates”), duly endorsed, along with a copy of the Notice of Conversion as soon as practicable
thereafter to the Corporation. Upon receipt by the Corporation of a facsimile copy of a Notice of
Conversion from a holder, the Corporation shall promptly send, via facsimile, a confirmation to
such holder stating that the Notice of Conversion has been received, the date upon which the
Corporation expects to deliver the Common Stock issuable upon such conversion and the name and
telephone number of a contact person at the Corporation regarding the conversion. The Corporation
shall not be obligated to issue shares of Common Stock upon a conversion unless either the
Preferred Stock Certificates are delivered to the Corporation as provided above, or the holder
notifies the Corporation that such Preferred Stock Certificates have been lost, stolen or destroyed
and delivers the documentation to the Corporation required by Article XV.B hereof.

          (i) Delivery of Common Stock Upon Conversion. Upon the surrender of Preferred Stock
Certificates accompanied by a Notice of Conversion, the Corporation (itself, or through its
transfer agent) shall, no later than the later of (a) the second business day following the
Conversion Date and (b) the business day following the date of such surrender (or, in the case of
lost, stolen or destroyed certificates, after provision of indemnity pursuant to Article XV.B) (the
“Delivery Period”), issue and deliver (i.e., deposit with a nationally recognized overnight courier
service postage prepaid) to the holder or its nominee (x) that number of shares of Common Stock
issuable upon conversion of such shares of Series B Preferred Stock being converted and (y) a

- 6 -

 

certificate representing the number of shares of Series B Preferred Stock not being converted, if
any. Notwithstanding the foregoing, if the Corporation’s transfer agent is participating in the
Depository Trust Company (“DTC”) Fast Automated Securities Transfer program, and so long as the
certificates therefor do not bear a legend (pursuant to the terms of the Series B Securities Purchase
Agreement) and the holder thereof is not then required to return such certificate for the placement
of a legend thereon (pursuant to the terms of the Series B Securities Purchase Agreement), the
Corporation shall cause its transfer agent to promptly electronically transmit the Common Stock
issuable upon conversion to the holder by crediting the account of the holder or its nominee with
DTC through its Deposit Withdrawal Agent Commission system (“DTC Transfer”). If the aforementioned
conditions to a DTC Transfer are not satisfied, the Corporation shall deliver as provided above to
the holder physical certificates representing the Common Stock issuable upon conversion. Further,
a holder may instruct the Corporation to deliver to the holder physical certificates representing
the Common Stock issuable upon conversion in lieu of delivering such shares by way of DTC Transfer.

          (ii) Taxes. The Corporation shall pay any and all taxes that may be imposed upon it
with respect to the issuance and delivery of the shares of Common Stock upon the conversion of the
Series B Preferred Stock.

          (iii) No Fractional Shares. If any conversion of Series B Preferred Stock would
result in the issuance of a fractional share of Common Stock (aggregating all shares of Series B
Preferred Stock being converted pursuant to a given Notice of Conversion), such fractional share
shall be payable in cash based upon the ten day average Closing Sales Price of the Common Stock at
such time, and the number of shares of Common Stock issuable upon conversion of the Series B
Preferred Stock shall be the next lower whole number of shares. If the Corporation elects not to,
or is unable to, make such a cash payment, the holder shall be entitled to receive, in lieu of the
final fraction of a share, one whole share of Common Stock.

          (iv) Conversion Disputes. In the case of any dispute with respect to a conversion,
the Corporation shall promptly issue such number of shares of Common Stock as are not disputed in
accordance with subparagraph (i) above. If such dispute involves the calculation of the Conversion
Price, and such dispute is not promptly resolved by discussion between the relevant holder and the
Corporation, the Corporation shall submit the disputed calculations to an independent outside
accountant via facsimile within three business days of receipt of the Notice of Conversion. The
accountant, at the Corporation’s sole expense, shall promptly audit the calculations and notify the
Corporation and the holder of the results no later than three business days from the date it
receives the disputed calculations. The accountant’s calculation shall be deemed conclusive,
absent manifest error. The Corporation shall then issue the appropriate number of shares of Common
Stock in accordance with subparagraph (i) above.

          (v) Payment of Accrued Amounts. Upon conversion of any shares of Series B Preferred
Stock, all amounts then accrued or payable on such shares under this Certificate of Designation
(including, without limitation, all Dividends) or the Registration Rights Agreement through and
including the Conversion Date shall be paid in cash by the Corporation or, in the case of any
Dividend, in the manner described in Article III.

- 7 -

 

V. RESERVATION OF SHARES OF COMMON STOCK

     A. Reserved Amount. On or prior to the Issuance Date, the Corporation shall reserve
10,000,000 shares of its authorized but unissued shares of Common Stock for issuance upon
conversion of the Series B Preferred Stock (including any Dividend payable thereon) and exercise of
the Warrants and, thereafter, the number of authorized but unissued shares of Common Stock so
reserved (the “Reserved Amount”) shall at all times be sufficient to provide for the full
conversion (including any Dividend payable thereon) of all of the Series B Preferred Stock
(including any Dividend payable thereon) outstanding at the then current Conversion Price thereof
(without giving effect to the limitations contained in Article XIV) and the full exercise of all
Warrants outstanding at the then current exercise price thereof (without giving effect to the
limitations on exercise set forth therein). The Reserved Amount shall be allocated among the
holders of Series B Preferred Stock as provided in Article XVI.C.

     B. Increases to Reserved Amount. If the Reserved Amount for any three consecutive
trading days (the last of such three trading days being the “Authorization Trigger Date”) shall be
less than one hundred percent (100%) of the number of shares of Common Stock issuable upon (i) full
conversion (including any Dividend payable thereon) of the then outstanding shares of Series B
Preferred Stock (without giving effect to the limitations contained in Article XIV) and (ii) full
exercise of all Warrants outstanding at the then current exercise price thereof (without giving
effect to the limitations on exercise set forth therein), the Corporation shall immediately notify
the holders of Series B Preferred Stock of such occurrence and shall take immediate action
(including, if necessary, seeking stockholder approval to authorize the issuance of additional
shares of Common Stock) to increase the Reserved Amount to one hundred percent (100%) of the number
of shares of Common Stock then issuable upon (i) full conversion of all of the outstanding Series B
Preferred Stock at the then current Conversion Price (without giving effect to the limitations
contained in Article XIV) and (ii) full exercise of all Warrants outstanding at the then current
exercise price thereof (without giving effect to the limitations on exercise set forth therein).
In the event the Corporation fails to so increase the Reserved Amount within 90 days after an
Authorization Trigger Date, each holder of Series B Preferred Stock shall thereafter have the
option, exercisable in whole or in part at any time and from time to time, by delivery of a
Redemption Notice to the Corporation, to require the Corporation to redeem for cash, at an amount
per share equal to the Redemption Amount (as defined in Article VII.B), a number of the holder’s
shares of Series B Preferred Stock such that, after giving effect to such redemption, the then
unissued portion of such holder’s Reserved Amount is at least equal to one hundred percent (100%)
of the total number of shares of Common Stock issuable upon conversion of such holder’s shares of
Series B Preferred Stock. If the Corporation fails to redeem any of such shares within five
business days after its receipt of such Redemption Notice, then such holder shall be entitled to
the remedies provided in Article VII.C. For the avoidance of doubt, no holder of Series B
Preferred Stock shall have the right to submit a Redemption Notice pursuant to this Article V.B at
any time that the Reserved Amount equals one hundred percent (100%) of the number of shares of
Common Stock then issuable upon full conversion (including any Dividend payable thereon) of all of
the outstanding Series B Preferred Stock at the then current Conversion Price (without giving
effect to the limitations contained in Article XIV).

- 8 -

 

VI. FAILURE TO SATISFY CONVERSIONS

     A. Conversion Defaults. If, at any time, (i) a holder of shares of Series B Preferred
Stock submits a Notice of Conversion and the Corporation fails for any reason (other than because
such issuance would exceed such holder’s allocated portion of the Reserved Amount, for which
failures the holders shall have the remedies set forth in Article V) to deliver, on or prior to the
fifth business day following the expiration of the Delivery Period for such conversion, such number
of freely tradable shares of Common Stock to which such holder is entitled upon such conversion, or
(ii) the Corporation provides written notice to any holder of Series B Preferred Stock (or makes a
public announcement via press release) at any time of its intention not to issue freely tradable
shares of Common Stock upon exercise by any holder of its conversion rights in accordance with the
terms of this Certificate of Designation (other than because such issuance would exceed such
holder’s allocated portion of the Cap Amount or Reserved Amount) (each of (i) and (ii) being a
“Conversion Default”), then the holder may elect, at any time and from time to time prior to the
Default Cure Date for such Conversion Default, by delivery of a Redemption Notice to the
Corporation, to have all or any portion of such holder’s outstanding shares of Series B Preferred
Stock redeemed by the Corporation for cash, at an amount per share equal to the Redemption Amount
(as defined in Article VII.B). If the Corporation fails to redeem any of such shares within five
business days after its receipt of such Redemption Notice, then such holder shall be entitled to
the remedies provided in Article VII.C.

     B. Buy-In Cure. Unless the Corporation has notified the applicable holder in writing
prior to the delivery by such holder of a Notice of Conversion that the Corporation is unable to
honor conversions, if (i) (a) the Corporation fails to promptly deliver during the Delivery Period
shares of Common Stock to a holder upon a conversion of shares of Series B Preferred Stock or (b)
there shall occur a Legend Removal Failure (as defined in Article VII.A(iii) below) and (ii)
thereafter, such holder purchases (in an open market transaction or otherwise) shares of Common
Stock to make delivery in satisfaction of a sale by such holder of the unlegended shares of Common
Stock (the “Sold Shares”) which such holder anticipated receiving upon such conversion (a
“Buy-In”), the Corporation shall pay such holder, in addition to any other remedies available to
the holder, the amount by which (x) such holder’s total purchase price (including brokerage
commissions, if any) for the unlegended shares of Common Stock so purchased exceeds (y) the net
proceeds received by such holder from the sale of the Sold Shares. For example, if a holder
purchases unlegended shares of Common Stock having a total purchase price of $11,000 to cover a
Buy-In with respect to shares of Common Stock it sold for $10,000, the Corporation will be required
to pay the holder $1,000. A holder shall provide the Corporation written notification and
supporting documentation indicating any amounts payable to such holder pursuant to this Article
VI.B.

VII. REDEMPTION DUE TO CERTAIN EVENTS

     A. Redemption by Holder. In the event (each of the events described in clauses
(i)-(viii) below after expiration of the applicable cure period (if any) being a “Redemption
Event”):

          (i) the Common Stock (including any of the shares of Common Stock issuable upon conversion of
the Series B Preferred Stock) is suspended from trading on any of, or is not listed

- 9 -

 

(and authorized) for trading on at least one of, the New York Stock Exchange, the American Stock
Exchange, the Nasdaq National Market or the Nasdaq SmallCap Market for an aggregate of ten or more
trading days in any twelve month period;

          (ii) the registration statement required to be filed by the Corporation pursuant to Section
2(a) of the Registration Rights Agreement has not been declared effective by the one hundred
twentieth (120th) day following the Issuance Date or such registration statement, after
being declared effective, cannot be utilized by the holders of Series B Preferred Stock for the
resale of all of their Registrable Securities (as defined in the Registration Rights Agreement) for
an aggregate of more than 15 days in the aggregate;

          (iii) the Corporation fails to remove any restrictive legend on any certificate or any shares
of Common Stock issued to the holders of Series B Preferred Stock upon conversion of the Series B
Preferred Stock as and when required by this Certificate of Designation, the Series B Securities
Purchase Agreement or the Registration Rights Agreement (a “Legend Removal Failure”), and any such
failure continues uncured for five business days after the Corporation has been notified thereof in
writing by the holder;

          (iv) the Corporation provides written notice (or otherwise indicates) to any holder of Series
B Preferred Stock, or states by way of public announcement distributed via a press release, at any
time, of its intention not to issue, or otherwise refuses to issue, shares of Common Stock to any
holder of Series B Preferred Stock upon conversion in accordance with the terms of this Certificate
of Designation;

          (v) the Corporation or any subsidiary of the Corporation shall make an assignment for the
benefit of creditors, or apply for or consent to the appointment of a receiver or trustee for it or
for a substantial part of its property or business, or such a receiver or trustee shall otherwise
be appointed;

          (vi) bankruptcy, insolvency, reorganization or liquidation proceedings or other proceedings
for the relief of debtors shall be instituted by or against the Corporation or any subsidiary of
the Corporation and if instituted against the Corporation or any subsidiary of the Corporation by a
third party, shall not be dismissed within 60 days of their initiation;

          (vii) the Corporation shall:

               (a) sell, convey or dispose of all or substantially all of its assets (the presentation of any
such transaction for stockholder approval being conclusive evidence that such transaction involves
the sale of all or substantially all of the assets of the Corporation);

               (b) merge or consolidate with or into, or engage in any other business combination with, any
other person or entity, in any case which results in either (i) the holders of the voting
securities of the Corporation immediately prior to such transaction holding or having the right to
direct the voting of fifty percent (50%) or less of the total outstanding voting securities of the
Corporation or such other surviving or acquiring person or entity immediately following such
transaction or (ii) the members of the board of directors or other governing body of the
Corporation

- 10 -

 

comprising fifty percent (50%) of less of the members of the board of directors or
other governing body of the Corporation or such other surviving or acquiring person or entity
immediately following such transaction;

               (c) either (i) fail to pay, when due, or within any applicable grace period, any payment with
respect to any indebtedness of the Corporation in excess of $250,000 due to any third party, other
than payments contested by the Corporation in good faith, or otherwise be in breach or violation of
any agreement for monies owed or owing in an amount in excess of $250,000 which breach or violation
permits the other party thereto to declare a default or otherwise accelerate amounts due
thereunder, or (ii) suffer to exist any other default or event of default under any agreement
binding the Corporation which default or event of default would or is likely to have a material
adverse effect on the business, operations, properties, prospects or financial condition of the
Corporation;

               (d) have fifty percent (50%) or more of the voting power of its capital stock owned
beneficially by one person, entity or “group” (as such term is used under Section 13(d) of the
Securities Exchange Act of 1934, as amended);

               (e) experience any Change of Control not otherwise addressed in subparagraphs (a)-(d) above;
or

          (viii) except with respect to matters covered by subparagraphs (i) – (vii) above, as to which
such applicable subparagraphs shall apply, the Corporation otherwise shall breach any material term
hereunder or under the Series B Securities Purchase Agreement, the Registration Rights Agreement,
the Warrants or the Note, including, without limitation, the representations and warranties
contained therein (i.e., in the event of a material breach as of the date such representation and
warranty was made) and if such breach is curable, shall fail to cure such breach within ten
business days after the Corporation has been notified thereof in writing by the holder;

then, upon the occurrence of any such Redemption Event, each holder of shares of Series B Preferred
Stock shall thereafter have the option, exercisable in whole or in part at any time and from time
to time by delivery of a written notice to such effect (a “Redemption Notice”) to the Corporation
while such Redemption Event continues, to require the Corporation to purchase for cash any or all
of the then outstanding shares of Series B Preferred Stock held by such holder for an amount per
share equal to the Redemption Amount (as defined in Paragraph B below) in effect at the time of the
redemption hereunder. For the avoidance of doubt, the occurrence of any event described in clauses
(i), (ii), (iv), (v), (vi) and (vii) above shall immediately constitute a Redemption Event and
there shall be no cure period. Upon the Corporation’s receipt of any Redemption Notice hereunder
(other than during the three trading day period following the Corporation’s delivery of a
Redemption Announcement (as defined below) to all of the holders in response to the Corporation’s
initial receipt of a Redemption Notice from a holder of Series B Preferred Stock), the Corporation
shall immediately (and in any event within one business day following such receipt) deliver a
written notice (a “Redemption Announcement”) to all holders of Series B Preferred Stock stating the
date upon which the Corporation received such Redemption Notice and the amount of Series B
Preferred Stock covered thereby. The Corporation shall not redeem any shares of Series B Preferred
Stock during the three trading day period following the delivery of a required Redemption
Announcement

- 11 -

 

hereunder. At any time and from time to time during such three trading day period,
each holder of Series B Preferred Stock may request (either orally or in writing) information from
the Corporation with respect to the instant redemption (including, but not limited to, the
aggregate number of shares of Series B Preferred Stock covered by Redemption Notices received by
the Corporation) and the
Corporation shall furnish (either orally or in writing) as soon as practicable such requested
information to such requesting holder.

     B. Definition of Redemption Amount. The “Redemption Amount” with respect to a share
of Series B Preferred Stock means an amount equal to the greater of:

	 	 	 	 	 	 	 	 	 	 	 
	 

	 	(i)
	 	V
	 	x
	 	M
	 	 
	 

	 	 	 	 	 	 	 	 	 	 
	 

	 	 	 	CP	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	and

	 	(ii)
	 	V
	 	x
	 	R	 	 

where:

          “V” means the Face Amount thereof plus all accrued Dividends thereon through the date of
payment of the Redemption Amount;

          “CP” means the Conversion Price in effect on the date on which the Corporation receives the
Redemption Notice;

          “M” means (i) with respect to all redemptions other than redemptions pursuant to subparagraph
(a) or (b) of Article VII.A(vii) hereof, the highest Closing Sales Price of the Corporation’s
Common Stock during the period beginning 10 trading days prior to the date on which the Corporation
receives the Redemption Notice and ending on the date immediately preceding the date of payment of
the Redemption Amount and (ii) with respect to redemptions pursuant to subparagraph (a) or (b) of
Article VII.A(vii) hereof, the greater of (a) the amount determined pursuant to clause (i) of this
definition or (b) the fair market value, as of the date on which the Corporation receives the
Redemption Notice, of the consideration payable to the holder of a share of Common Stock pursuant
to the transaction which triggers the redemption. For purposes of this definition, “fair market
value” shall be determined by the mutual agreement of the Corporation and the Series B Majority
Holders, or if such agreement cannot be reached within five business days prior to the date of
redemption, by an investment banking firm selected by the Corporation and reasonably acceptable to
the Series B Majority Holders, with the costs of such appraisal to be borne by the Corporation; and

          “R” means 115%, except in the case of a Redemption Event described in Article VII.A.(vii), in
which case “R” means 150%.

     C. Redemption Defaults. If the Corporation fails to pay any holder the Redemption
Amount with respect to any share of Series B Preferred Stock within five business days after its
receipt of a Redemption Notice, then the holder of Series B Preferred Stock entitled to redemption
shall be entitled to interest on the Redemption Amount at a per annum rate equal to the lower of

- 12 -

 

eighteen percent (18%) and the highest interest rate permitted by applicable law from the date on
which the Corporation receives the Redemption Notice until the date of payment of the Redemption
Amount hereunder. In the event the Corporation is not able to redeem all of the shares of Series B
Preferred Stock subject to Redemption Notices delivered prior to the date upon which such
redemption is to be effected, the Corporation shall redeem shares of Series B Preferred Stock
from each holder pro rata, based on the total number of shares of Series B Preferred Stock
outstanding at the time of redemption included by such holder in all Redemption Notices delivered
prior to the date upon which such redemption is to be effected relative to the total number of
shares of Series B Preferred Stock outstanding at the time of redemption included in all of the
Redemption Notices delivered prior to the date upon which such redemption is to be effected.

VIII. RANK

     All shares of the Series B Preferred Stock shall rank (i) prior to the Corporation’s Common
Stock and any class or series of capital stock of the Corporation hereafter created (unless, with
the consent of the Series B Majority Holders obtained in accordance with Article XIII hereof, such
class or series of capital stock specifically, by its terms, ranks senior to or pari passu with the
Series B Preferred Stock) (collectively with the Common Stock, “Junior Securities”); (ii) pari
passu with (a) the Corporation’s Series A Convertible Preferred Stock and (b) any class or series
of capital stock of the Corporation hereafter created (with the written consent of the Series B
Majority Holders obtained in accordance with Article XII hereof) specifically ranking, by its
terms, on parity with the Series B Preferred Stock (the “Pari Passu Securities”); and (iii) junior
to any class or series of capital stock of the Corporation hereafter created (with the written
consent of the Series B Majority Holders obtained in accordance with Article XII hereof)
specifically ranking, by its terms, senior to the Series B Preferred Stock (collectively, the
“Senior Securities”), in each case as to distribution of assets upon liquidation, dissolution or
winding up of the Corporation, whether voluntary or involuntary.

IX. LIQUIDATION PREFERENCE

     A. Priority in Liquidation. In the event that the Corporation shall liquidate,
dissolve or wind up its affairs (a “Liquidation Event”), no distribution shall be made to the
holders of any shares of capital stock of the Corporation (other than Senior Securities pursuant to
the rights, preferences and privileges thereof) upon liquidation, dissolution or winding up unless
prior thereto the holders of shares of Series B Preferred Stock shall have received the Liquidation
Preference with respect to each share. If, upon the occurrence of a Liquidation Event, the assets
and funds available for distribution among the holders of the Series B Preferred Stock and holders
of Pari Passu Securities, if any, shall be insufficient to permit the payment to such holders of
the preferential amounts payable thereon, then the entire assets and funds of the Corporation
legally available for distribution to the Series B Preferred Stock and the Pari Passu Securities,
if any, shall be distributed ratably among such shares in proportion to the ratio that the
Liquidation Preference payable on each such share bears to the aggregate Liquidation Preference
payable on all such shares. If, upon the occurrence of a Liquidation Event, the assets and funds
available for distribution among the holders of Senior Securities, if any, the holders of the
Series B Preferred Stock and the holders of Pari Passu Securities, if any, shall be sufficient to
permit the payment to such holders of the preferential

- 13 -

 

amounts payable thereon, then after such
payment shall be made in full to the holders of Senior Securities, if any, the holders of the
Series B Preferred Stock and the holders of Pari Passu Securities, if any, the remaining assets and
funds available for distribution shall be distributed ratably among the holders of shares of Series
B Preferred Stock, the holders of any other class or series of Preferred Stock entitled to
participate with the Common Stock in a liquidating distribution and the holders of the Common Stock, with the
holders of shares of Preferred Stock deemed to hold the number of shares of Common Stock into which
such shares of Preferred Stock are then convertible.

     B. Definition of Liquidation Preference. The “Liquidation Preference” with respect to
a share of Series B Preferred Stock means the greater of (i) an amount equal to one and one-half
(1.5) multiplied by the Face Amount thereof, and (ii) the amount that would be distributed in such
Liquidation Event on the number of shares of Common Stock into which a share of Series B Preferred
Stock could be converted immediately prior to such Liquidation Event, assuming all shares of Series
B Preferred Stock were so converted. The Liquidation Preference with respect to any Pari Passu
Securities, if any, shall be as set forth in the Certificate of Designation filed in respect
thereof.

X. ADJUSTMENTS TO THE CONVERSION PRICE

     The Conversion Price shall be subject to adjustment from time to time as follows:

     A. Stock
Splits, Stock Dividends, Etc. If, at any time on or after the Issuance Date,
the number of outstanding shares of Common Stock is increased by a stock split, stock dividend,
combination, reclassification or other similar event, the Conversion Price shall be proportionately
reduced, or if the number of outstanding shares of Common Stock is decreased by a reverse stock
split, combination, reclassification or other similar event, the Conversion Price shall be
proportionately increased. In such event, the Corporation shall notify the Corporation’s transfer
agent of such change on or before the effective date thereof.

     B. Change
of Control. If, at any time after the Issuance Date, there shall be a
Change of Control, then the holders of Series B Preferred Stock shall thereafter have the right to
receive upon conversion, in lieu of the shares of Common Stock otherwise issuable, such shares of
stock, securities and/or other property as would have been issued or payable in such Change of
Control with respect to or in exchange for the number of shares of Common Stock which would have
been issuable upon conversion had such Change of Control not taken place (without giving effect to
the limitations contained in Article XIV), and in any such case, appropriate provisions (in form
and substance reasonably satisfactory to the Series B Majority Holders) shall be made with respect
to the rights and interests of the holders of the Series B Preferred Stock to the end that the
economic value of the shares of Series B Preferred Stock are in no way diminished by such Change of
Control and that the provisions hereof (including, without limitation, in the case of any such
consolidation, merger or sale in which the successor entity or purchasing entity is not the
Corporation, an immediate adjustment of the Conversion Price so that the Conversion Price
immediately after the Change of Control reflects the same relative value as compared to the value
of the surviving entity’s common stock that existed between the Conversion Price and the value of
the Corporation’s Common Stock immediately prior to such Change of Control) shall thereafter be
applicable, as nearly as may be practicable in relation to any shares of stock or securities
thereafter deliverable

- 14 -

 

upon the conversion thereof. The Corporation shall not effect any Change of
Control unless (i) each holder of Series B Preferred Stock has received written notice (the “Change
of Control Notice”) of such transaction at least 30 days prior thereto, but in no event later than
10 days prior to the record date for the determination of stockholders entitled to vote with
respect thereto, and (ii) the resulting successor or acquiring entity (if not the
Corporation) assumes by written instrument (in form and substance reasonable satisfactory to
the Series B Majority Holders) the obligations of this Certificate of Designation (including,
without limitation, the obligation to make payments of Dividends accrued but unpaid through the
date of such Change of Control and accruing thereafter). The above provisions shall apply
regardless of whether or not there would have been a sufficient number of shares of Common Stock
authorized and available for issuance upon conversion of the shares of Series B Preferred Stock
outstanding as of the date of such transaction, and shall similarly apply to successive
reclassifications, consolidations, mergers, sales, transfers or share exchanges.

     C. Distributions. If, at any time after the Issuance Date, the Corporation shall
declare or make any distribution of its assets (or rights to acquire its assets) to holders of
Common Stock as a partial liquidating dividend, by way of return of capital or otherwise (including
any dividend or distribution to the Corporation’s stockholders in cash or shares (or rights to
acquire shares) of capital stock of a subsidiary (i.e., a spin-off)) (a “Distribution”), then the
holders of Series B Preferred Stock shall be entitled, upon any conversion of shares of Series B
Preferred Stock after the date of record for determining stockholders entitled to such Distribution
(or if no such record is taken, the date on which such Distribution is declared or made), to
receive the amount of such assets which would have been payable to the holder with respect to the
shares of Common Stock issuable upon such conversion (without giving effect to the limitations
contained in Article XIV) had such holder been the holder of such shares of Common Stock on the
record date for the determination of stockholders entitled to such Distribution (or if no such
record is taken, the date on which such Distribution is declared or made).

     D. Convertible Securities and Purchase Rights. If, at any time after the Issuance
Date, the Corporation issues any securities or other instruments which are convertible into or
exercisable or exchangeable for Common Stock (“Convertible Securities”) or options, warrants or
other rights to purchase or subscribe for Common Stock or Convertible Securities (“Purchase
Rights”) pro rata to the record holders of any class of Common Stock, whether or not such
Convertible Securities or Purchase Rights are immediately convertible, exercisable or exchangeable,
then the holders of Series B Preferred Stock shall be entitled to acquire, upon the terms
applicable to such Convertible Securities or Purchase Rights, the aggregate number of Convertible
Securities or Purchase Rights which such holder could have acquired if such holder had held the
number of shares of Common Stock acquirable upon complete conversion of the Series B Preferred
Stock (without giving effect to the limitations contained in Article XIV) immediately before the
date on which a record is taken for the grant, issuance or sale of such Convertible Securities or
Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common
Stock are to be determined for the grant, issue or sale of such Convertible Securities or Purchase
Rights.

     E. Other Action Affecting Conversion Price. If, at any time after the Issuance Date,
the Corporation takes any action affecting the Common Stock that would be covered by Article X.A
through D, but for the manner in which such action is taken or structured, which would in any way
diminish the value of the Series B Preferred Stock, then the Conversion Price shall be adjusted in

- 15 -

 

such manner as the Board of Directors of the Corporation shall in good faith determine to be
equitable under the circumstances.

     F. Notice of Adjustments. Upon the occurrence of each adjustment or readjustment of
the Conversion Price pursuant to this Article X amounting to a more than one percent (1%)
change in such Conversion Price, or any change in the number or type of stock, securities and/or
other property issuable upon conversion of the Series B Preferred Stock, the Corporation, at its
expense, shall promptly compute such adjustment or readjustment or change and prepare and furnish
to each holder of Series B Preferred Stock a certificate setting forth such adjustment or
readjustment or change and showing in detail the facts upon which such adjustment or readjustment
or change is based. The Corporation shall, upon the written request at any time of any holder of
Series B Preferred Stock, furnish to such holder a like certificate setting forth (i) such
adjustment or readjustment or change, (ii) the Conversion Price at the time in effect and (iii) the
number of shares of Common Stock and the amount, if any, of other securities or property which at
the time would be received upon conversion of a share of Series B Preferred Stock.

XI. VOTING RIGHTS AND BOARD REPRESENTATION

     A. Voting Rights.

          (i) Except as otherwise expressly provided elsewhere in this Certificate of Designation or as
otherwise required by the Delaware General Corporation Law (the “DGCL”), (a) each holder of Series
B Preferred Stock shall be entitled to vote on all matters submitted to a vote of the stockholders
of the Corporation and shall be entitled to that number of votes equal to the number of shares of
Common Stock into which such holder’s shares of Series B Preferred Stock could then be converted
(subject to the limitations set forth in Article XIV) at the record date for the determination of
stockholders entitled to vote on such matters or, if no such record date is established, at the
date such vote is taken or any written consent of stockholders is solicited, and (b) the holders of
shares of Series B Preferred Stock and Common Stock shall vote together (or tender written consents
in lieu of a vote) as a single class on all matters submitted to the stockholders of the
Corporation. Fractional votes shall not, however, be permitted and any fractional voting rights
available on an as-converted basis (after aggregating all shares of Common Stock into which shares
of Series B Preferred Stock held by each holder could be converted) shall be rounded to the nearest
whole number.

          (ii) The Corporation shall provide each holder of Series B Preferred Stock with prior
notification of any meeting of the stockholders (and copies of proxy materials and other
information sent to stockholders). If the Corporation takes a record of its stockholders for the
purpose of determining stockholders entitled to (a) receive payment of any dividend or other
distribution, any right to subscribe for, purchase or otherwise acquire (including by way of
merger, consolidation or recapitalization) any share of any class or any other securities or
property, or to receive any other right, or (b) to vote in connection with any proposed sale, lease
or conveyance of all or substantially all of the assets of the Corporation, or any proposed merger,
consolidation, liquidation, dissolution or winding up of the Corporation, the Corporation shall
mail a notice to each holder of Series B Preferred Stock, at least 15 days prior to the record date
specified therein (or 45

- 16 -

 

days prior to the consummation of the transaction or event, whichever is
earlier, but in no event earlier than public announcement of such proposed transaction), of the
date on which any such record is to be taken for the purpose of such vote, dividend, distribution,
right or other event, and a brief statement regarding the amount and character of such vote,
dividend, distribution, right or other event to the extent known at such time.

          (iii) To the extent that under the DGCL the vote of the holders of the Series B Preferred
Stock, voting separately as a class or series, as applicable, is required to authorize a given
action of the Corporation, the affirmative vote or consent of the holders of at least a majority of
the then outstanding shares of the Series B Preferred Stock represented at a duly held meeting at
which a quorum is present or by written consent of the Series B Majority Holders (except as
otherwise may be required under the DGCL) shall constitute the approval of such action by the
class.

     B. Board Representation. The holders of Series B Preferred Stock, exclusively and as
a separate class, shall be entitled to elect one member of the Board (the “Series B Director”).
The director elected to the Board of Directors by the Series A Convertible Preferred Stockholders
shall initially serve as the Series B Director. The Series B Director may be removed without cause
by, and only by, the affirmative vote of the holders of Series B Preferred Stock, given either at a
special meeting of the holders of Series B Preferred Stock duly called for that purpose, or by
written consent of the holders of Series B Preferred Stock. So long as any shares of Series B
Preferred Stock are outstanding, the Company shall not enter into any definitive agreement
providing for, or consummate any Change of Control transaction unless the holders of Series B
Preferred Stock, exclusively and as a separate class of securities, shall be entitled to elect one
or more member of the board of directors (or equivalent board) of the acquirer or successor entity,
as the case may be, holding at least the same proportional voting power in respect of such board of
such entity as the Series B Director held in respect of the Board of Directors immediately prior to
the consummation of such Change of Control.

     C. Board Observation. The holders of Series B Preferred Stock, exclusively and as a
separate class, shall be entitled to designate one observer (an “Observer”) to attend all meetings
of the Board and all committees thereof. The Board will give the Observer reasonable prior notice
(it being agreed that the same prior notice given to the Board shall be deemed reasonable prior
notice) in any matter permitted by the Corporation’s bylaws for notice to directors of the time and
place of any proposed meeting of the Board, and such notice in all cases shall include true and
correct copies of all documents furnished to any director in connection with such meeting. The
Observer will be entitled to be present in person as an observer to any such meeting or, if a
meeting is held by telephone conference or other electronic means, to participate therein for the
purpose of listening thereto. The Corporation will deliver to the Observer copies of all documents
that may be distributed from time to time to the members of the Board (in their capacity as such)
at such time as such papers are so distributed to them, including copies of any written consent.
The Observer shall hold in confidence to the same extent required by law of the members of the
Board all documents furnished in connection with any meeting of the Board and any committee thereof
and all information received through oral communication in any meeting of the Board and any
committee thereof.

     D. Investment Oversight Committee. The investment oversight committee established
pursuant to the Corporation’s Certificate of Designation, Preferences and Rights of Series A
Convertible Preferred Stock is hereby terminated and a new investment oversight committee (the

- 17 -

 

“Investment Oversight Committee”) is hereby established for the purpose of monitoring the
disbursement of the net proceeds to the Corporation from transactions pursuant to the Series A
Securities Purchase Agreement and Series B Securities Purchase Agreement. The Investment Oversight
Committee shall consist of two (2) members, one of whom shall be appointed by the Board
and one of whom shall be appointed by the holders of Series B Preferred Stock. The initial
members shall be W. Michael Smith and Raahim Don. All expenditures of the proceeds resulting from
the sales of securities by the Corporation pursuant to the Series A Securities Purchase Agreement
and Series B Securities Purchase Agreement shall require the unanimous, prior, written approval of
the members of the Investment Oversight Committee. The Investment Oversight Committee shall remain
in existence until the Company has used all of the proceeds received in connection with the
transactions contemplated by the Series B Securities Purchase Agreement.

XII. PROTECTION PROVISIONS

     So long as any shares of Series B Preferred Stock are outstanding, the Corporation shall not
take any of the following corporate actions (whether by merger, consolidation or otherwise) without
first obtaining the approval (by vote or written consent, as provided by the DGCL) of the Series B
Majority Holders:

          (i) alter or change the rights, preferences or privileges of the Series B Preferred Stock, or
increase the authorized number of shares of Series B Preferred Stock;

          (ii) amend its certificate of incorporation or bylaws;

          (iii) issue any shares of Series B Preferred Stock other than pursuant to the Series B
Securities Purchase Agreement or as a Dividend (as described in Article III);

          (iv) redeem, repurchase or otherwise acquire, or declare or pay any cash dividend or
distribution on, any Junior Securities;

          (v) increase the par value of the Common Stock;

          (vi) sell all or substantially all of its assets or stock, or consolidate or merge with
another entity;

          (vii) enter into or permit to occur any Change of Control transaction;

          (viii) sell, transfer or encumber technology, other than licenses granted in the ordinary
course of business;

          (ix) liquidate, dissolve, recapitalize or reorganize;

          (x) authorize, reserve, or issue Common Stock with respect to any plan or agreement that
provides for the issuance of equity securities to employees, officers, directors or consultants of
the Corporation in excess of 250,000 shares of Common Stock, which figure equals the number of
shares of Common Stock currently reserved for issuance under such plans and

- 18 -

 

arrangements;

          (xi) change its principal business;

          (xii) issue shares of Common Stock, other than as contemplated herein or by the Warrants;

          (xiii) increase the number of members of the Board to more than 7 members, or, if no Series B
Director has been elected, increase the number of members of the Board to more than 6 members;

          (xiv) alter or change the rights, preferences or privileges of any capital stock of the
Corporation so as to affect adversely the Series B Preferred Stock;

          (xv) create or issue any Senior Securities or Pari Passu Securities;

          (xvi) except for the issuance of debt securities on an unsecured basis to, or incurrence of
unsecured indebtedness from, a recognized financial institution in an aggregate amount not
exceeding $5,000,000 and which, in the case of debt securities, are not Convertible Securities or
Purchase Rights, issue any debt securities or incur any indebtedness that would have any
preferences over the Series B Preferred Stock upon liquidation of the Corporation, or redeem,
repurchase, prepay or otherwise acquire any outstanding debt securities or indebtedness of the
Corporation, except as expressly required by the terms of such securities or indebtedness;

          (xvii) make any Dilutive Issuance;

          (xviii) enter into any agreement, commitment, understanding or other arrangement to take any
of the foregoing actions; or

          (xix) cause or authorize any subsidiary of the Corporation to engage in any of the foregoing
actions.

Notwithstanding the foregoing, no corporate action pursuant to this Article XII shall be effective
to the extent that, by its terms, it applies to less than all of the holders of shares of Series B
Preferred Stock then outstanding.

XIII. OPTIONAL REDEMPTION

     A. If, at any time after the first anniversary of the Issuance Date and before the fourth
anniversary of the Issuance Date, on each trading day during a period of at least twenty (20)
consecutive trading days (a) the Closing Sales Price of the Common Stock is at least 200% of the
Conversion Price then in effect and (b) the trading volume (as reported by Bloomberg) and Market
Price of the Common Stock result in a value of at least $350,000 of Common Stock traded on each
trading day, then the Corporation shall have the right to redeem all shares of Series B Preferred
Stock then outstanding at price per share of Series B Preferred Stock equal to the product of two
multiplied by the sum of the Face Amount plus all accrued and unpaid
Dividends thereon through the closing

- 19 -

 

date of such redemption.

     B. Any redemption made by the Corporation pursuant to this Article XIII (the
“Company Redemption”) shall be made by providing forty-five (45) days’ advance written notice
(the “Company Redemption Notice”) to the holders of shares of Series B Preferred Stock. The
Corporation may redeem all, but not less than all, of the outstanding shares of Series B Preferred
Stock pursuant to this Article XIII.

     C. The Corporation may not deliver to a holder a Company Redemption Notice unless (a) the
conditions to such Company redemption have been satisfied within the twenty (20) trading day period
preceding such Company Redemption Notice, and (ii) on or prior to the date of delivery of such
Company Redemption Notice, the Corporation shall have segregated on the books and records of the
Corporation an amount of cash sufficient to pay all amounts to which the holders of shares of
Series B Preferred Stock are entitled upon such redemption pursuant to this Article XIII. Any
Company Redemption Notice delivered shall be irrevocable and shall be accompanied by a certificate
executed by a duly authorized officer of the Corporation stating that all conditions to such
Company Redemption have been satisfied.

     D. The price per share of Series B Preferred Stock required to be paid by the Corporation
pursuant to Article XIII.A (the “Company Redemption Amount”) shall be paid in cash to the holders
whose Series B Preferred Stock is being redeemed within five (5) business days of the effective
date of the Company Redemption (the “Company Redemption Date”); provided, however, that the
Corporation shall not be obligated to deliver any portion of the Company Redemption Amount until
either the Preferred Stock Certificates being redeemed are delivered to the office of the
Corporation or the holder notifies the Corporation that such certificates have been lost, stolen or
destroyed and delivers the appropriate documentation in accordance with Article XVI.B hereof.
Notwithstanding anything herein to the contrary, in the event that the Preferred Stock Certificates
representing the shares of Series B Preferred Stock being redeemed are not delivered to the
Corporation or the transfer agent or the holder fails to notify the Corporation or the transfer
agent that such certificates have been lost, stolen or destroyed and fails to deliver the
appropriate documentation in accordance with Article XV.B hereof prior to the fifth business day
following the Company Redemption Date, then the redemption of the Series B Preferred Stock pursuant
to this Article XIII shall still be deemed effective as of the Company Redemption Date, but the
Company Redemption Amount shall be paid in cash to the holder whose shares of Series B Preferred
Stock are being redeemed only within five (5) business days of the date the Preferred Stock
Certificates representing such shares are actually delivered to the Corporation or the transfer
agent or the holder notifies the Corporation that such Preferred Stock Certificates have been lost,
stolen or destroyed and delivers the documentation to the Corporation required by Article XVI.B
hereof.

     E. Notwithstanding the delivery of a Company Redemption Notice, a holder may convert some or
all of its shares of Series B Preferred Stock subject to such Company Redemption Notice by the
delivery at least three trading days prior to the Company Redemption Date of a Notice of

- 20 -

 

Conversion to the Corporation and otherwise complying with all requirements set forth in Article IV. In the
event a holder would be precluded from converting any shares of Series B Preferred Stock subject to
a Company Redemption Notice due to the limitation contained in Article XIV, the Company Redemption
Date, for such holder only, shall automatically be extended by that number of
days by which such holder is so precluded; provided, however, that in no event shall the
Company Redemption Date be extended by more than sixty (60) days.

XIV. LIMITATIONS ON CERTAIN CONVERSIONS AND TRANSFERS

     In no event shall a holder of shares of Series B Preferred Stock of the Corporation have the
right to convert shares of Series B Preferred Stock into shares of Common Stock or to dispose of
any shares of Series B Preferred Stock to the extent that such right to effect such conversion or
disposition would result in the holder and its affiliates together beneficially owning or having
the power to vote more than 9.99% of the outstanding shares of Common Stock. For purposes of this
Article XIV, beneficial ownership shall be determined in accordance with Section 13(d) of the
Securities Exchange Act of 1934, as amended, and Regulation 13D-G thereunder. The restriction
contained in this Article XIV may not be altered, amended, deleted or changed in any manner
whatsoever unless the holders of a majority of the outstanding shares of Common Stock and the
Series B Majority Holders shall approve, in writing, such alteration, amendment, deletion or
change.

XV. PARTICIPATION RIGHT; EXCHANGE RIGHT

     Subject to the terms and conditions specified in this Article XV, the holders of Series B
Preferred Stock shall have a right to participate with respect to the issuance or possible issuance
of (i) equity or equity-linked securities, or (ii) debt that is convertible into equity or in which
there is an equity component (“Additional Securities”) on the same terms and conditions as offered
by the Company to the other purchasers of such Additional Securities. Each time the Company
proposes to offer any Additional Securities, the Company shall make an offering of such Additional
Securities to each Purchaser in accordance with the following provisions:

          (i) the Company shall deliver a notice (the “Notice”) to the holders of Series B Preferred
Stock stating (A) its bona fide intention to offer such Additional Securities, (B) the number of
such Additional Securities to be offered, (C) the price and terms, if any, upon which it proposes
to offer such Additional Securities, and (D) the anticipated closing date of the sale of such
Additional Securities;

          (ii) until the second anniversary of the Closing Date, by written notification received by the
Company within fifteen (15) trading days after giving of the Notice, any holder of Series B
Preferred Stock may elect to purchase or obtain, at the price and on the terms specified in the
Notice, up to that portion of such Additional Securities that have a total purchase price equal to
the greater of (1) fifty percent (50%) of the aggregate amount of the Additional Securities to be
offered and sold in such offering and (2) one hundred percent (100%) of the Face Amount of the
Series B Preferred Stock then held by such holder (including any shares of Series B Preferred Stock
that have been converted into Common Stock), plus any accrued and unpaid Dividends. The

- 21 -

 

Company
shall promptly, in writing, inform each holder of Series B Preferred Stock that elects to purchase
all of the Additional Shares available to it (“Fully-Exercising Holder”) of any other holder of
Series B Preferred Stock’s failure to do likewise. During the five (5) trading day period
commencing after such information is given, each Fully-Exercising Holder shall be entitled to
obtain that portion of the Additional Securities for which the holders of Series B Preferred Stock
were entitled to subscribe but that were not subscribed for by the holders of Series B Preferred
Stock that is equal to the proportion that the Face Amount of the Series B Preferred Stock held by
such Fully-Exercising Holder (including any shares of Series B Preferred Stock that have been
converted into Common Stock) bears to the total Face Amount of the Series B Preferred Stock held by
all holders of Series B Preferred Stock (including any shares of Series B Preferred Stock that have
been converted into Common Stock);

          (iii) notwithstanding the provisions of Article XV(ii), at any time after the Closing Date, by
written notification received by the Company within five (5) trading days after giving of the
Notice required by Article XV(i) above, any holder of Series B Preferred Stock may elect to
purchase or obtain, at the price and on the terms specified in the Notice, up to that portion of
such Additional Securities that have a total purchase price equal to the Face Amount of the Series
B Preferred Stock held by such holder (including any shares of Series B Preferred Stock that have
been converted into Common Stock), plus accrued and unpaid Dividends; provided, however, that any
holder of Series B Preferred Stock who elects to purchase Additional Securities pursuant to this
Article XV(iii) shall be required to surrender to the Company Series B Preferred Stock (or Common
Stock issued on the conversion of such Series B Preferred Stock) for which the Face Amount (plus
all accrued but unpaid Dividends) equals the total purchase price of the Additional Securities to
be acquired by such holder of Series B Preferred Stock under this paragraph (iii), and the Company
shall accept such Series B Preferred Stock (or Common Stock issued on the conversion of such Series
B Preferred Stock) as payment in full for such Additional Securities. The provisions of this
Article XV(iii) shall be of no further force or effect upon the consummation of any transaction
(other than those transactions contemplated by the Series B Securities Purchase Agreement)
resulting in the issuance of the Company’s Common Stock in connection with a bona fide public
offering at an offering price per share (prior to any underwriter’s commissions and discounts) of
not less than $3.10 (as adjusted to reflect any stock dividends, distributions, combinations,
reclassifications and other similar transactions effected by the Company in respect to its Common
Stock) that results in total net proceeds to the Company of at least $25,000,000;

          (iv) if all Additional Securities which the holders of Series B Preferred Stock are entitled
to obtain pursuant to Article XV(ii) or Article XV(iii) are not elected to be obtained as provided
in subsection Article XV(ii) or Article XV(iii) hereof, the Company may, during the 75-day period
following the expiration of the period provided in subsection Article XV(ii) or Article XV(iii)
hereof, offer the remaining unsubscribed portion of such Additional Securities to any person or
persons at a price not less than, and upon terms no more favorable to the offeree than, those
specified in the Notice. If the Company does not consummate the sale of such Additional Securities
within such period, the right provided hereunder shall be deemed to be revived and such Additional
Securities shall not be offered or sold unless first reoffered to the holders of Series B Preferred
Stock in accordance herewith;

          (v) the participation rights in this Article XV shall not be applicable to (A) the

- 22 -

 

issuance or sale of shares of Common Stock (or options therefor) to employees, officers, directors, or
consultants of the Company for the primary purpose of soliciting or retaining their employment or
service pursuant to a stock option plan (or similar equity incentive plan) approved in good faith
by the Board of Directors, (B) the issuance of Common Stock in connection with a bona fide
underwritten public offering at an offering price per share (prior to underwriter’s commissions and
discounts) of not less than 200% of the Conversion Price (as adjusted to reflect any stock
dividends, distributions, combinations, reclassifications and other similar transactions effected
by the Company in respect to its Common Stock) that results in total proceeds to the Company of at
least $25,000,000, (C) the issuance or sale of the Series B Preferred Stock, (D) the issuance of
securities in connection with mergers, acquisitions, strategic business partnerships or joint
ventures approved by the Board of Directors and the primary purpose of which, in the reasonable
judgment of the Board of Directors, is not to raise additional capital or (E) any issuance of
securities as to which the Series B Majority Holders shall have executed a written waiver of the
rights contained in this Article XV; and

          (vi) the participation rights set forth in this Article XV may not be assigned or transferred,
except that such right is assignable by each holder of Series B Preferred Stock to any wholly-owned
subsidiary or parent of, or to any corporation or entity that is, within the meaning of the
Securities Act, controlling, controlled by or under common control with, any such holder of Series
B Preferred Stock.

XVI. MISCELLANEOUS

     A. Cancellation of Series B Preferred Stock. If any shares of Series B Preferred
Stock are converted pursuant to Article IV, exchanged pursuant to Article XV(iii) or redeemed or
repurchased by the Corporation, the shares so converted or redeemed shall be canceled, shall return
to the status of authorized, but unissued Preferred Stock of no designated series, and shall not be
issuable by the Corporation as Series B Preferred Stock.

     B. Lost or Stolen Certificates. Upon receipt by the Corporation of (i) evidence of
the loss, theft, destruction or mutilation of any Preferred Stock Certificate(s) and (ii) (y) in
the case of loss, theft or destruction, indemnity (without any bond or other security) reasonably
satisfactory to the Corporation, or (z) in the case of mutilation, the Preferred Stock
Certificate(s) (surrendered for cancellation), the Corporation shall execute and deliver new
Preferred Stock Certificate(s) of like tenor and date. However, the Corporation shall not be
obligated to reissue such lost, stolen, destroyed or mutilated Preferred Stock Certificate(s) if
the holder contemporaneously requests the Corporation to convert such Series B Preferred Stock.

     C. Allocation of Reserved Amount. The initial Reserved Amount shall be allocated pro
rata among the holders of Series B Preferred Stock based on the number of shares of Series B
Preferred Stock issued to each such holder. Each increase to the Reserved Amount shall be
allocated pro rata among the holders of Series B Preferred Stock based on the number of shares of
Series B Preferred Stock held by each holder at the time of the increase in the Reserved Amount.
In the event a holder shall sell or otherwise transfer any of such holder’s shares of Series B
Preferred Stock, each transferee shall be allocated a pro rata portion of such transferor’s
Reserved Amount. Any portion of the Reserved Amount that remains allocated to any person or entity
which does not hold any Series B

- 23 -

 

Preferred Stock shall be allocated to the remaining holders of
shares of Series B Preferred Stock, pro rata based on the number of shares of Series B Preferred
Stock then held by such holders.

     D. Quarterly Statements of Available Shares. For each calendar quarter beginning in
the quarter in which the initial registration statement required to be filed pursuant to Section
2(a) of the
Registration Rights Agreement is declared effective and thereafter for so long as any shares
of Series B Preferred Stock are outstanding, the Corporation shall deliver (or cause its transfer
agent to deliver) to each holder a written report notifying the holders of any reason why the
Corporation is prohibited from issuing Common Stock upon any conversion. The report shall also
specify (i) the total number of shares of Series B Preferred Stock outstanding as of the end of
such quarter, (ii) the total number of shares of Common Stock issued upon all conversions of Series
B Preferred Stock prior to the end of such quarter, (iii) the total number of shares of Common
Stock which are reserved for issuance upon conversion of the Series B Preferred Stock as of the end
of such quarter and (iv) the total number of shares of Common Stock which may thereafter be issued
by the Corporation upon conversion of the Series B Preferred Stock before the Corporation would
exceed the Cap Amount and the Reserved Amount. The Corporation (or its transfer agent) shall use
commercially reasonable efforts to deliver the report for each quarter to each holder prior to the
tenth day of the calendar month following the quarter to which such report relates. In addition,
the Corporation (or its transfer agent) shall provide, as promptly as practicable following
delivery to the Corporation of a written request by any holder, any of the information enumerated
in clauses (i) — (iv) of this Paragraph D as of the date of such request.

     E. Payment of Cash; Defaults. Whenever the Corporation is required to make any cash
payment to a holder under this Certificate of Designation (as payment of any Dividend, upon
redemption or otherwise), such cash payment shall be made to the holder within five business days
after delivery by such holder of a notice specifying the method (e.g., by check, wire transfer) in
which such payment should be made and any supporting documentation reasonably requested by the
Corporation to substantiate the holder’s claim to such cash payment and the amount thereof. If
such payment is not delivered within such five business day period, such holder shall thereafter be
entitled to interest on the unpaid amount at a per annum rate equal to the lower of (i) eighteen
percent (18%) and (ii) the highest interest rate permitted by applicable law until such amount is
paid in full to the holder.

     F. Status as Stockholder. Upon submission of a Notice of Conversion by a holder of
Series B Preferred Stock, (i) the shares covered thereby (other than the shares, if any, which
cannot be issued because their issuance would exceed such holder’s allocated portion of the
Reserved Amount or Cap Amount) shall be deemed converted into shares of Common Stock and (ii) the
holder’s rights as a holder of such converted shares of Series B Preferred Stock shall cease and
terminate, excepting only the right to receive certificates for such shares of Common Stock and to
any remedies provided herein or otherwise available at law or in equity to such holder because of a
failure by the Corporation to comply with the terms of this Certificate of Designation.
Notwithstanding the foregoing, if a holder has not received certificates for all shares of Common
Stock prior to the sixth business day after the expiration of the Delivery Period with respect to a
conversion of Series B Preferred Stock for any reason, then (unless the holder otherwise elects to
retain its status as a holder of Common Stock by so notifying the Corporation within five business
days after the expiration of such six business day period after expiration of the Delivery Period)
the

- 24 -

 

holder shall regain the rights of a holder of Series B Preferred Stock with respect to such
unconverted shares of Series B Preferred Stock and the Corporation shall, as soon as practicable,
return such unconverted shares to the holder. In all cases, the holder shall retain all of its
rights and remedies for the Corporation’s failure to convert Series B Preferred Stock.

     G. Remedies Cumulative. The remedies provided in this Certificate of Designation
shall be cumulative and in addition to all other remedies available under this Certificate of
Designation, at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit a holder’s right to pursue actual damages for
any failure by the Corporation to comply with the terms of this Certificate of Designation. The
Corporation acknowledges that a breach by it of its obligations hereunder will cause irreparable
harm to the holders of Series B Preferred Stock and that the remedy at law for any such breach may
be inadequate. The Corporation therefore agrees, in the event of any such breach or threatened
breach, that the holders of Series B Preferred Stock shall be entitled, in addition to all other
available remedies, to an injunction restraining any breach, without the necessity of showing
economic loss and without any bond or other security being required.

     H. Waiver. Notwithstanding any provision in this Certificate of Designation to the
contrary, any provision contained herein and any right of the holders of Series B Preferred Stock
granted hereunder may be waived as to all shares of Series B Preferred Stock (and the holders
thereof) upon the written consent of the Series B Majority Holders, unless a higher percentage is
required by applicable law, in which case the written consent of the holders of not less than such
higher percentage of shares of Series B Preferred Stock shall be required.

     I. Notices. Any notices required or permitted to be given under the terms hereof
shall be sent by certified or registered mail (return receipt requested) or delivered personally,
by nationally recognized overnight carrier or by confirmed facsimile transmission, and shall be
effective five days after being placed in the mail, if mailed, or upon receipt or refusal of
receipt, if delivered personally or by nationally recognized overnight carrier or, subject to
Section II.D. hereof, upon confirmed facsimile transmission, in each case addressed to a party.
The addresses for such communications are (i) if to the Corporation to Remote Dynamics, Inc., 1155
Kas Drive, Suite 100, Richardson, Texas 75081-1999, Telephone: 972-301-2733, Facsimile:
972-301-2263, Attention: J. Raymond Bilbao, Esquire, and (ii) if to any holder to the address set
forth under such holder’s name on the execution page to the Series B Securities Purchase Agreement,
or such other address as any party may be designated in writing hereafter, in the same manner, by
such person.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

- 25 -

 

     IN WITNESS WHEREOF, this Certificate of Designation is executed on behalf of the Corporation
this 1st day of September, 2005.

	 	 	 	 	 
	 	 	REMOTE DYNAMICS, INC.
	 
	 	 	 	 
	 

	 	By:
	 	/s/ W. Michael Smith
	 

	 	 	 	 
	 	 	Name: W. Michael Smith
	 	 	Title: COO

 

 

NOTICE OF CONVERSION

(To be Executed by the Registered Holder

in order to Convert the Series B Preferred Stock)

     The undersigned hereby irrevocably elects to convert ___shares of Series B Preferred
Stock (the “Conversion”), represented by Stock Certificate No(s). ___(the “Preferred Stock
Certificates”), into shares of common stock (“Common Stock”) of Remote Dynamics, Inc. (the
“Corporation”) and cash in lieu of any fractional share(s), if applicable, according to the
conditions of the Certificate of Designation, Preferences and Rights of Series B Convertible
Preferred Stock (the “Certificate of Designation”), as of the date written below. If securities
are to be issued in the name of a person other than the undersigned, the undersigned will pay all
transfer taxes payable with respect thereto. No fee will be charged to the holder for any
conversion, except for transfer taxes, if any. Each Preferred Stock Certificate is attached hereto
(or evidence of loss, theft or destruction thereof).

     Except as may be provided below, the Corporation shall electronically transmit the Common
Stock issuable pursuant to this Notice of Conversion to the account of the undersigned or its
nominee (which is ___) with DTC through its Deposit Withdrawal Agent Commission
System (“DTC Transfer”).

     In the event of partial exercise, please reissue a new stock certificate for the number of
shares of Series B Preferred Stock which shall not have been converted.

     The undersigned acknowledges and agrees that all offers and sales by the undersigned of the
securities issuable to the undersigned upon conversion of the Series B Preferred Stock have been or
will be made only pursuant to an effective registration of the transfer of the Common Stock under
the Securities Act of 1933, as amended (the “Act”), or pursuant to an exemption from registration
under the Act.

	o	 	In lieu of receiving the shares of Common Stock issuable pursuant to this Notice of
Conversion by way of DTC Transfer, the undersigned hereby requests that the Corporation issue
and deliver to the undersigned physical certificates representing such shares of Common Stock.

	 	 	 	 	 
	 

	 	Date of Conversion:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Applicable Conversion Price:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Signature:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Name:	 	 
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	Address:exv10w1

 

Exhibit 10.1

EXECUTION VERSION

SECURITIES PURCHASE AGREEMENT

     This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of May 31, 2005, is made by and
among Remote Dynamics, Inc., a corporation organized under the laws of the State of Delaware (the
“Company”), and the purchaser (the “Purchaser”) set forth on the execution page hereof (the
“Execution Page”).

BACKGROUND

     A. The Company and the Purchaser are executing and delivering this Agreement in reliance upon
the exemption from securities registration afforded by the provisions of Regulation D (“Regulation
D”), as promulgated by the United States Securities and Exchange Commission (the “SEC”) under the
Securities Act of 1933, as amended (the “Securities Act”).

     B. Upon the terms and conditions stated in this Agreement:

          1. the Purchaser desires to exchange the 5,000 shares of the Company’s Series A Convertible
Preferred Stock, par value $.01 per share (the “Series A Preferred Stock”), and pay an additional
$750,000 in cash to the Company, in exchange for (i) 650 shares of the Company’s Series B
Convertible Preferred Stock, par value $.01 per share (the “Series B Preferred Stock”), which
Series B Preferred Stock shall have the rights, preferences and privileges set forth in the form of
Certificate of Designation, Preferences and Rights attached hereto as Exhibit A (the
“Series B Certificate of Designation”), and (ii) a warrant in the form attached hereto as
Exhibit B (the “C-3 Warrant”) to purchase 2,000,000 shares of the Company’s common stock,
par value $.01 per share (the “Common Stock”); and the Company desires to issue such shares of
Series B Preferred Stock and the C-3 Warrant in such exchange; and

          2. the Company desires to borrow from the Purchaser, and the Purchaser desires to loan to the
Company, additional cash in the amount of $1,750,000 in exchange for a senior secured note
exchangeable, under certain circumstances, for two warrants to purchase up to an aggregate of
2,366,667 shares of Common Stock, in the forms attached hereto as Exhibit C (the “C-1
Warrant”) and Exhibit D (the “C-2 Warrant”); and the Company desires to issue the Note to
the Purchaser in exchange for such funds.

The C-1 Warrant and the C-2 Warrant are together referred to herein as the “Exchange Warrants.” The
C-3 Warrant and the Exchange Warrants are together referred to herein as the “Warrants.” The
shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants are referred
to herein as the “Warrant Shares.” The shares of Common Stock issuable upon exercise of or
otherwise pursuant to the Exchange Warrants are referred to herein as the “Exchange Warrant
Shares.” The shares of Common Stock issuable upon conversion of or otherwise pursuant to the
Series B Preferred Stock are referred to herein as the “Preferred Conversion Shares.” The
Preferred Conversion Shares and the Warrant Shares are together referred to herein as the
“Underlying Common Shares.” The Series B Preferred Stock, the

 

 

Note, the Warrants and the Underlying Common Shares are collectively referred to herein as the
“Securities” and each of them may individually be referred to herein as a “Security.”

     C. Concurrently with the execution of this Agreement and the Note, the parties hereto are
executing a Security Agreement in the form attached hereto as Exhibit E (the “Security
Agreement”).

     D. Pursuant to the terms of this Agreement, as a condition to the sale of the Series B Stock
and the C-3 Warrant hereunder, the parties hereto intend to execute a Registration Rights
Agreement, in the form attached hereto as Exhibit F (the “Registration Rights Agreement”),
pursuant to which the Company shall agree to provide certain registration rights under the
Securities Act and the rules and regulations promulgated thereunder, and applicable state
securities laws. This Agreement, the Series B Certificate of Designation, the Warrants, the Note,
the Registration Rights Agreement and the Security Agreement are collectively referred to herein as
the “Transaction Documents.”

     NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the Company and the Purchaser, intending to be legally bound, hereby agree as
follows:

	1.	 	PURCHASE AND SALE OF SECURITIES.

     (a) Issuance of Note. Subject to the terms hereof, concurrently with the execution of
this Agreement (i) the Purchaser shall pay One Million Seven Hundred Fifty Thousand Dollars
($1,750,000) to the Company, and the Company shall issue the Note to the Purchaser; and (ii) the
Purchaser and the Company shall execute and deliver the Security Agreement.

     (b) Sale of Series B Preferred Stock. Subject to the terms and conditions hereof,
including the conditions set forth in Sections 6 and 7, the Purchaser shall surrender and exchange
all of the 5,000 shares of Series A Preferred Stock held by the Purchaser and shall pay an
additional Seven Hundred Fifty Thousand Dollars ($750,000) (the “Series B Purchase Price”) to the
Company, and the Company shall issue 650 shares of Series B Preferred Stock and the C-3 Warrant to
the Purchaser (the issuance of the Series B Preferred Stock hereunder shall be deemed full
satisfaction, and result in cancellation, of the Series A Preferred Stock); and

     (c) Exchange of Note for Warrants. Subject to the terms and conditions hereof,
including Sections 6 and 7, and the terms and conditions of the Note, the Purchaser shall surrender
the Note to the Company, and in exchange for the Note the Company shall issue to the Purchaser the
C-1 and C-2 Warrants (the “Exchange”).

     (d) The Closings. The closings of the transactions contemplated in each of Section
1(b) hereof (the “Series B Closing”) and Section 1(c) hereof (the “Exchange Closing,” and together
with the Series B Closing, the “Closings”) shall take place at the offices of Drinker Biddle &
Reath LLP at One Logan Square, 18th & Cherry Streets, Philadelphia, Pennsylvania 19103
at 10:00 a.m., Philadelphia, Pennsylvania time, on the business day immediately following the day
on which all of the applicable conditions set forth in Sections 6 and 7 below

- 2 -

 

are satisfied or waived or such other time or place as the Company and the Purchaser may
mutually agree (the “Series B Closing Date” or “Exchange Closing Date,” as applicable; each, a
“Closing Date”).

	2.	 	PURCHASER’S REPRESENTATIONS AND WARRANTIES.

     The Purchaser represents and warrants to the Company as follows:

     (a) Purchase for Own Account, Etc. The Purchaser is purchasing the Securities for the
Purchaser’s own account for investment purposes only and not with a present view towards the public
sale or distribution thereof, except pursuant to sales that are exempt from the registration
requirements of the Securities Act and/or sales registered under the Securities Act. The Purchaser
understands that the Purchaser must bear the economic risk of this investment indefinitely, unless
the Securities are registered pursuant to the Securities Act and any applicable state securities or
blue sky laws or an exemption from such registration is available, and that the Company has no
present intention of registering the resale of any such Securities other than as contemplated by
the Registration Rights Agreement. Notwithstanding anything in this Section 2(a) to the contrary,
by making the representations herein, the Purchaser does not agree to hold the Securities for any
minimum or other specific term and reserves the right to dispose of the Securities at any time in
accordance with or pursuant to a registration statement or an exemption from the registration
requirements under the Securities Act and applicable state securities laws.

     (b) Accredited Investor Status. The Purchaser is an “Accredited Investor” as that
term is defined in Rule 501(a) of Regulation D.

     (c) Reliance on Exemptions. The Purchaser understands that the Securities are being
offered and sold to the Purchaser in reliance upon specific exemptions from the registration
requirements of United States federal and state securities laws and that the Company is relying
upon the truth and accuracy of, and the Purchaser’s compliance with, the representations,
warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in
order to determine the availability of such exemptions and the eligibility of the Purchaser to
acquire the Securities.

     (d) Information. The Purchaser and its counsel, if any, have been furnished all
materials relating to the business, finances and operations of the Company and materials relating
to the offer and sale of the Securities that have been specifically requested by the Purchaser or
its counsel. Neither such inquiries nor any other investigation conducted by the Purchaser or its
counsel or any of its representatives shall modify, amend or affect the Purchaser’s right to rely
on the Company’s representations and warranties contained in Section 3 below. The Purchaser
understands that the Purchaser’s investment in the Securities involves a high degree of risk.

     (e) Governmental Review. The Purchaser understands that no United States federal or
state agency or any other government or governmental agency has passed upon or made any
recommendation or endorsement of the Securities.

     (f) Authorization; Enforcement. This Agreement has been duly and validly authorized,
executed and delivered on behalf of the Purchaser and is a valid and binding

- 3 -

 

agreement of the Purchaser enforceable against the Purchaser in accordance with its terms.
Each of the other Transaction Documents has been duly and validly authorized and, when executed and
delivered on behalf of the Purchaser at the Closing in accordance with this Agreement, shall be a
valid and binding agreement of the Purchaser enforceable against the Purchaser in accordance with
its respective terms.

     (g) Residency. The Purchaser is a resident of the jurisdiction set forth under the
Purchaser’s name on the Execution Page hereto executed by the Purchaser.

     (h) Experience of the Purchaser. The Purchaser, either alone or together with its
representatives, has such knowledge, sophistication, and experience in business and financial
matters so as to be capable of evaluating the merits and risks of the prospective investment in the
Securities, and has so evaluated the merits and risks of such investment.

     (i) Ability of the Purchaser to Bear Risk of Investment. The Purchaser is able to
bear the economic risk of an investment in the Securities and, at the present time, is able to
afford a complete loss of such investment.

     (j) Title to Series A Preferred Stock. The Purchaser has, and immediately prior to
the date of the Series B Closing, will have good and valid title to the shares of Series A
Preferred Stock to be exchanged by the Purchaser hereunder on the Series B Closing Date, free and
clear of all liens, encumbrances, equities or claims.

     (k) No Brokers. Other than the consulting fee to Saffron Capital Management LLC
referred to in Section 4(q), the Purchaser has taken no action that would give rise to any claim by
any person for brokerage commissions, finder’s fees or similar payments by the Company relating to
this Agreement or the transactions contemplated hereby.

     The Purchaser’s representations and warranties made in this Article 2 are made solely for the
purpose of permitting the Company to make a determination that the offer and sale of the Securities
pursuant to this Agreement comply with applicable U.S. federal and state securities laws and not
for any other purpose. Accordingly, the Company may not rely on such representations and
warranties for any other purpose. No Purchaser has made or hereby makes any other representations
or warranties, express or implied, to the Company in connection with the transactions contemplated
hereby.

	3.	 	REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

     Except as set forth on a Disclosure Schedule executed and delivered by the Company to the
Purchaser (the “Disclosure Schedule”) concurrently herewith, the Company represents and warrants to
the Purchaser as follows:

     (a) Organization and Qualification. The Company and each of its direct and indirect
subsidiaries (collectively, the “Subsidiaries”) is a corporation duly organized and existing in
good standing under the laws of the jurisdiction in which it is incorporated or organized, and has
the requisite corporate power to own its properties and to carry on its business as now being
conducted. The Company and each of its Subsidiaries is duly qualified as a foreign corporation

- 4 -

 

to do business and is in good standing in every jurisdiction in which the nature of the
business conducted by it makes such qualification necessary and where the failure so to qualify or
be in good standing would have a Material Adverse Effect. For purposes of this Agreement,
“Material Adverse Effect” means any effect which, individually or in the aggregate with all other
effects, reasonably would be expected to be materially adverse to (i) the sale, issuance or value
of the Securities, (ii) the ability of the Company to perform its obligations under this Agreement
or the other Transaction Documents or (iii) the business, operations, properties, prospects,
financial condition or results of operations of the Company and its Subsidiaries, taken as a whole;
provided, however, that any such effect resulting solely from changes affecting the economy or
financial markets generally shall not constitute a Material Adverse Effect.

     (b) Authorization; Enforcement. (i) The Company has the requisite corporate power and
authority to enter into and perform its obligations under this Agreement and the other Transaction
Documents, to issue and sell the Securities in accordance with the terms hereof, to issue the
Conversion Shares upon conversion of the Series B Preferred Stock in accordance with the terms
thereof and to issue the Warrant Shares upon exercise of the Warrants in accordance with the terms
thereof; (ii) the execution, delivery and performance of this Agreement and the other Transaction
Documents by the Company and the consummation by it of the transactions contemplated hereby and
thereby (including, without limitation, the issuance of the Securities and the issuance and
reservation for issuance of the Underlying Common Shares) have been duly authorized by the
Company’s Board of Directors and no further consent or authorization of the Company, its Board of
Directors, or any committee of the Board of Directors is required, and (iii) this Agreement
constitutes, and, upon execution and delivery by the Company of the other Transaction Documents,
such Transaction Documents will constitute, valid and binding obligations of the Company
enforceable against the Company in accordance with their terms. Neither the execution, delivery or
performance by the Company of its obligations under this Agreement or the other Transaction
Documents, nor the consummation by it of the transactions contemplated hereby or thereby
(including, without limitation, the issuance of the Securities or the issuance or reservation for
issuance of the Underlying Common Shares) requires any consent or authorization of the Company’s
stockholders.

     (c) Capitalization. The capitalization of the Company as of the date hereof,
including the authorized capital stock, the number of shares issued and outstanding, the number of
shares issuable and reserved for issuance pursuant to the Company’s stock option plans (including
the Company’s 2005 Equity Incentive Plan), the number of shares issuable and reserved for issuance
pursuant to securities (other than the Series B Preferred Stock and the Warrants) exercisable or
exchangeable for, or convertible into, any shares of capital stock and the number of shares to be
reserved for issuance upon conversion of the Series B Preferred Stock and exercise of the Warrants
is set forth in Section 3(c) of the Disclosure Schedule. All of such outstanding shares of
capital stock have been, or upon issuance in accordance with the terms of any such exercisable,
exchangeable or convertible securities will be, validly issued, fully paid and non-assessable. No
shares of capital stock of the Company (including the Conversion Shares and the Warrant Shares) are
subject to preemptive rights or any other similar rights of the stockholders of the Company or any
liens or encumbrances. Except for the Securities and as set forth in Section 3(c) of the
Disclosure Schedule, (i) there are no outstanding options, warrants, scrip, rights to subscribe to,
calls or commitments of any character whatsoever relating to, or securities or rights convertible
into or exercisable or exchangeable for, any shares of capital stock of the Company

- 5 -

 

or any of its Subsidiaries, or contracts, commitments, understandings or arrangements by which
the Company or any of its Subsidiaries is or may become bound to issue additional shares of capital
stock of the Company or any of its Subsidiaries, nor are any such issuances, contracts,
commitments, understandings or arrangements contemplated, (ii) there are no contracts, commitments,
understandings or arrangements under which the Company or any of its Subsidiaries is obligated to
register the sale of any of its or their securities under the Securities Act (except the
Registration Rights Agreement); (iii) there are no outstanding securities or instruments of the
Company or any of its Subsidiaries which contain any redemption or similar provisions, and there
are no contracts, commitments, understandings or arrangements by which the Company or any of its
Subsidiaries is or may become bound to redeem or otherwise acquire any security of the Company or
any of its Subsidiaries; and (iv) the Company does not have any shareholder rights plan, “poison
pill” or other anti-takeover plans. Section 3(c) of the Disclosure Schedule sets forth all
of the securities or instruments issued by the Company or any of its Subsidiaries that contain
anti-dilution or similar provisions, and, except as and to the extent set forth thereon, the sale
and issuance of the Securities will not trigger any anti-dilution adjustments to any such
securities or instruments. The Company has furnished to the Purchaser true and correct copies of
the Company’s Certificate of Incorporation as in effect on the date hereof (“Certificate of
Incorporation”), the Company’s Bylaws as in effect on the date hereof (the “Bylaws”), and all other
instruments and agreements governing securities convertible into or exercisable or exchangeable for
capital stock of the Company, all of which instruments and agreements are set forth in Section
3(c) of the Disclosure Schedule. The Company or one of its Subsidiaries has the unrestricted
right to vote, and (subject to limitations imposed by applicable law) to receive dividends and
distributions on, all capital securities of its Subsidiaries as owned by the Company or any such
Subsidiary.

     (d) Issuance of Securities. The Securities are duly authorized and, upon issuance in
accordance with the terms of this Agreement, (i) will be validly issued, fully paid and
non-assessable and free from all taxes, liens, claims and encumbrances, (ii) will not be subject to
preemptive rights, rights of first refusal or other similar rights of stockholders of the Company
or any other person and (iii) will not impose personal liability on the holder thereof. The
Underlying Common Shares are duly authorized and reserved for issuance, and, upon conversion of the
Series B Preferred Stock and exercise of the Warrants in accordance with the terms thereof, (x)
will be validly issued, fully paid and non-assessable, and free from all taxes, liens, claims and
encumbrances, (y) will not be subject to preemptive rights, rights of first refusal or other
similar rights of stockholders of the Company or any other person and (z) will not impose personal
liability upon the holder thereof.

     (e) No Conflicts; Consents. The execution, delivery and performance of this Agreement
and the other Transaction Documents by the Company and the consummation by the Company of the
transactions contemplated hereby and thereby (including, without limitation, the issuance of the
Securities and the issuance and reservation for issuance of the Underlying Common Shares) will not
(i) result in a violation of the Certificate of Incorporation or Bylaws, (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment (including, without limitation, the
triggering of any anti-dilution provisions), acceleration or cancellation of, any agreement,
indenture or instrument to which the Company or any of its Subsidiaries is a party, or (iii)
assuming the receipt of the Nasdaq Listing Department’s approval

- 6 -

 

of the Company’s Supplemental Listing Application with respect to the Securities (other than
the Note), subject to stockholder approval (to the extent stockholder approval is contemplated
herein), result in a violation of any law, rule, regulation, order, judgment or decree (including
United States federal and state securities laws, rules and regulations and rules and regulations of
any self-regulatory organizations to which either the Company or its securities are subject)
applicable to the Company or any of its Subsidiaries or by which any property or asset of the
Company or any of its Subsidiaries is bound or affected (except, with respect to clauses (ii) and
(iii), for such conflicts, defaults, terminations, amendments, accelerations, cancellations and
violations that would not, individually or in the aggregate, have a Material Adverse Effect).
Except (v) for Listing Department approval of the Supplemental Listing Application, (w) as may be
required under the Securities Act in connection with the performance of the Company’s obligations
under the Registration Rights Agreement, (x) for the filing of a Form D with the SEC, (y) as may be
required for compliance with applicable state securities or “blue sky” laws, or (z) as otherwise
set forth in Section 3(e) of the Disclosure Schedule, the Company is not required to obtain
any consent, approval, authorization or order of, or make any filing or registration with, any
court or governmental agency or any regulatory or self-regulatory agency or other third party
(including, without limitation, pursuant to any Material Contract (as defined in Section 3(g)
below)) in order for it to execute and deliver this Agreement or any of the other Transaction
Documents or perform any of its obligations hereunder or thereunder.

     (f) Compliance. The Company is not in violation of its Certificate of Incorporation,
Bylaws or other organizational documents and no Subsidiary is in violation of any of its
organizational documents. Neither the Company nor any of its Subsidiaries is in default (and no
event has occurred that with notice or lapse of time or both would put the Company or any of its
Subsidiaries in default) under, nor has there occurred any event giving others (with notice or
lapse of time or both) any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which the Company or any of its Subsidiaries is a party
(including, without limitation, the Material Contracts), except for actual or possible violations,
defaults or rights that would not, individually or in the aggregate, have a Material Adverse
Effect. The businesses of the Company and its Subsidiaries are not being conducted in violation of
any law, ordinance or regulation of any governmental entity, except for possible violations the
sanctions for which either individually or in the aggregate have not had and would not have a
Material Adverse Effect. Neither the Company, nor any of its Subsidiaries, nor any director,
officer, agent, employee or other person acting on behalf of the Company or any Subsidiary has, in
the course of his actions for, or on behalf of, the Company or any Subsidiary, used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to
political activity, made any direct or indirect unlawful payment to any foreign or domestic
government official or employee from corporate funds, violated or is in violation of any provision
of the U.S. Foreign Corrupt Practices Act of 1977, or made any bribe, rebate, payoff, influence
payment, kickback or other unlawful payment to any foreign or domestic government official or
employee. The Company and its Subsidiaries possess all certificates, authorizations and permits
issued by the appropriate federal, state, provincial or foreign regulatory authorities that are
material to the conduct of its business, and neither the Company nor any of its Subsidiaries has
received any notice of proceeding relating to the revocation or modification of any such
certificate, authorization or permit.

- 7 -

 

     (g) SEC Documents, Financial Statements. Since August 31, 2001, the Company has
timely filed (within applicable extension periods) all reports, schedules, forms, statements and
other documents required to be filed by it with the SEC pursuant to the reporting requirements of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (all of the foregoing filed
prior to the date hereof and all exhibits included therein and financial statements and schedules
thereto and documents incorporated by reference therein, the “SEC Documents”). The Company has
delivered to the Purchaser true and complete copies of the SEC Documents, or such documents are
available on EDGAR. As of their respective dates, the SEC Documents complied in all material
respects with the requirements of the Exchange Act or the Securities Act, as the case may be, and
the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and
none of the SEC Documents, at the time they were filed with the SEC, contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in light of the circumstances under which they were made,
not misleading. None of the statements made in any such SEC Documents is, or has been, required to
be amended or updated under applicable law (except for such statements as have been amended or
updated in subsequent filings made prior to the date hereof). As of their respective dates, the
financial statements of the Company included in the SEC Documents complied as to form in all
material respects with applicable accounting requirements and the published rules and regulations
of the SEC applicable with respect thereto. Such financial statements have been prepared in
accordance with U.S. generally accepted accounting principles (“GAAP”), consistently applied,
during the periods involved (except as may be otherwise indicated in such financial statements or
the notes thereto or, in the case of unaudited interim statements, to the extent they may not
include footnotes or may be condensed or summary statements) and fairly present in all material
respects the consolidated financial position of the Company and its consolidated Subsidiaries as of
the dates thereof and the consolidated results of their operations and cash flows for the periods
then ended (subject, in the case of unaudited statements, to normal, immaterial year-end audit
adjustments). Except as set forth in the financial statements of the Company included in the
Select SEC Documents (as defined below), the Company has no liabilities, contingent or otherwise,
other than (i) liabilities incurred in the ordinary course of business subsequent to the date of
such financial statements and (ii) obligations under contracts and commitments incurred in the
ordinary course of business and not required under GAAP to be reflected in such financial
statements, which liabilities and obligations referred to in clauses (i) and (ii), individually or
in the aggregate, are not material to the financial condition or operating results of the Company.
Without limiting the generality of the foregoing, the Company has either satisfied or has set aside
on its books and records provisions reasonably adequate for the satisfaction of all Claims (as
defined in the Plan of Reorganization) pursuant to the Company’s Third Amended Joint Plan of
Reorganization, dated June 28, 2004 (the “Plan of Reorganization”). To the extent required by the
rules and regulations of the SEC applicable thereto, the Select SEC Documents contain a complete
and accurate list of all material undischarged written or oral contracts, agreements, leases or
other instruments to which the Company or any Subsidiary is a party or by which the Company or any
Subsidiary is bound or to which any of the properties or assets of the Company or any Subsidiary is
subject (each, a “Material Contract”). Except as set forth in the Select SEC Documents, none of
the Company, its Subsidiaries or, to the best knowledge of the Company, any of the other parties
thereto is in breach or violation of any Material Contract, which breach or violation would have a
Material Adverse Effect. For purposes of this Agreement, “Select SEC

- 8 -

 

Documents” means the Company’s (A) Annual Report on Form 10-K for the fiscal year ended August
31, 2004, as amended by the Form 10-K/A filed on December 23, 2004 (the “2004 Annual Report”), (B)
Quarterly Reports on Form 10-Q for the fiscal quarters ended November 30, 2004 and February 29,
2005 and (C) Current Reports on Form 8-K filed since August 31, 2004.

     (h) Internal Accounting Controls. Although the Company has not implemented, and is
not yet required to implement, the requirements of Section 404 of the Sarbanes-Oxley Act of 2002
and the rules and regulations promulgated thereunder, the Company and each of its Subsidiaries
maintains a system of internal accounting controls sufficient to provide reasonable assurance that
(i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only
in accordance with management’s general or specific authorization, and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. The Company has established
disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the
Company and designed such disclosures controls and procedures to ensure that material information
relating to the Company, including its Subsidiaries, is made known to the certifying officers by
others within those entities, particularly during the period in which the Company’s Annual Report
on Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The
Company’s certifying officers have evaluated the effectiveness of the Company’s controls and
procedures as of a date within 90 days prior to the filing date of the 2004 Annual Report and the
Company’s most recently filed Quarterly Report on Form 10-Q (each such date, an “Evaluation Date”).
The Company presented in the 2004 Annual Report and its most recently filed Quarterly Report on
Form 10-Q the conclusions of the certifying officers about the effectiveness of the disclosure
controls and procedures based on their evaluations as of the respective Evaluation Date. Since the
Evaluation Date for the 2004 Annual Report, there have been no significant changes in the Company’s
“internal controls” (as such term is defined in Item 307(b) of Regulation S-K under the Exchange
Act) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s
internal controls.

     (i) Absence of Certain Changes. Except as set forth in the Select SEC Documents,
since August 31, 2004, there has been no material adverse change and no material adverse
development in the business, properties, operations, prospects, financial condition or results of
operations of the Company and its Subsidiaries, taken as a whole. The Company does not currently
expect to take any steps to seek protection pursuant to any bankruptcy or receivership law, nor
does the Company or any of its Subsidiaries have any knowledge or reason to believe that its
creditors intend to initiate involuntary bankruptcy proceedings with respect to the Company or any
of its Subsidiaries.

     (j) Transactions With Affiliates. Except as set forth in the Select SEC Documents,
none of the officers, directors, or employees of the Company or any of its Subsidiaries is
presently a party to any transaction with the Company or any of its Subsidiaries (other than for
ordinary course services solely in their capacity as officers, directors or employees), including
any contract, agreement or other arrangement providing for the furnishing of services to or by,
providing for rental of real or personal property to or from, or otherwise requiring payments to or

- 9 -

 

from any such officer, director or employee or any corporation, partnership, trust or other
entity in which any such officer, director, or employee has an ownership interest of five percent
or more or is an officer, director, trustee or partner.

     (k) Absence of Litigation. Except as disclosed in the Select SEC Documents and as set
forth in Section 3(k) of the Disclosure Schedule, there is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory
organization or body (including, without limitation, the SEC) pending or, to the knowledge of the
Company or any of its Subsidiaries, threatened against or affecting the Company, any of its
Subsidiaries, or any of their respective directors or officers in their capacities as such. There
are no facts which, if known by a potential claimant or governmental authority, could give rise to
a claim or proceeding which, if asserted or conducted with results unfavorable to the Company or
any of its Subsidiaries, could reasonably be expected to have a Material Adverse Effect.

     (l) Intellectual Property. Each of the Company and its Subsidiaries owns or is duly
licensed (and, in such event, has the unfettered right to grant sublicenses) to use all patents,
patent applications, trademarks, trademark applications, trade names, service marks, copyrights,
copyright applications, licenses, permits, inventions, discoveries, processes, scientific,
technical, engineering and marketing data, object and source codes, know-how (including trade
secrets and other unpatented and/or unpatentable proprietary or confidential information, systems
or procedures) and other similar rights and proprietary knowledge (collectively, “Intangibles”)
necessary for the conduct of its business as now being conducted and as presently contemplated to
be conducted in the future. Section 3(l) of the Disclosure Schedule sets forth a list of
all Intangibles owned and/or used by the Company in its business. To the knowledge of the Company
and its Subsidiaries, neither the Company nor any Subsidiary of the Company infringes or is in
conflict with any right of any other person with respect to any third party Intangibles. Neither
the Company nor any of its Subsidiaries has received written notice of any pending conflict with or
infringement upon such third party Intangibles. Except as set forth on Section 3(l) of the
Disclosure Schedule, neither the Company nor any of its Subsidiaries has entered into any consent
agreement, indemnification agreement, forbearance to sue or settlement agreement with respect to
the validity of the Company’s or its Subsidiaries’ ownership of or right to use its Intangibles and
the Company has no knowledge of any reasonable basis for any such claim to be successful. The
Intangibles are valid and enforceable and no registration relating thereto has lapsed, expired or
been abandoned or canceled or is the subject of cancellation or other adversarial proceedings, and
all applications therefor are pending and in good standing. The Company and its Subsidiaries have
complied, in all material respects, with their respective contractual obligations relating to the
protection of the Intangibles used pursuant to licenses. To the Company’s knowledge, no person is
infringing on or violating the Intangibles owned or used by the Company or its Subsidiaries.

     (m) Title. The Company and its Subsidiaries have good and marketable title in fee
simple to all real property and good and merchantable title to all personal property owned by them
that is material to the business of the Company and its Subsidiaries, in each case free and clear
of all liens, encumbrances and defects except such as do not materially affect the value of such
property and do not materially interfere with the use made and proposed to be made of such property
by the Company and its Subsidiaries. Any real property and facilities held under lease by the
Company and its Subsidiaries are held by them under valid, subsisting and enforceable

- 10 -

 

leases with such exceptions as are not material and do not materially interfere with the use
made and proposed to be made of such property and buildings by the Company and its Subsidiaries.

     (n) Tax Status. Except as set forth in the Select SEC Documents, the Company and each
of its Subsidiaries has made or filed all foreign, U.S. federal, state, provincial and local income
and all other tax returns, reports and declarations required by any jurisdiction to which it is
subject (unless and only to the extent that the Company and each of its Subsidiaries has set aside
on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and
has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being
contested in good faith and has set aside on its books provisions reasonably adequate for the
payment of all taxes for periods subsequent to the periods to which such returns, reports or
declarations apply. Except as set forth on Section 3(n) of the Disclosure Schedule, there
are no unpaid taxes in any material amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company know of no basis for any such claim. The Company has
not executed a waiver with respect to any statute of limitations relating to the assessment or
collection of any foreign, federal, state, provincial or local tax. None of the Company’s tax
returns is presently being audited by any taxing authority.

     (o) Key Employees. Each of the Company’s directors and officers and any Key Employee
(as defined below) is currently serving the Company in the capacity disclosed in the Select SEC
Documents. No Key Employee is, or is now expected to be, in violation of any material term of any
employment contract, confidentiality, disclosure or proprietary information agreement,
non-competition agreement, or any other contract or agreement or any restrictive covenant, and the
continued employment of each Key Employee does not subject the Company or any of its Subsidiaries
to any material liability with respect to any of the foregoing matters. Each Key Employee has
entered into an employment contract with the Company that provides for a term of employment as set
forth on Section 3(o) of the Disclosure Schedule. To the knowledge of the Company and its
Subsidiaries, no Key Employee has any intention to terminate or limit his employment with, or
services to, the Company or any of its Subsidiaries, nor is any such Key Employee subject to any
constraints which would cause such employee to be unable to devote his full time and attention to
such employment or services. For purposes of this Agreement, “Key Employee” means the persons
listed in Section 3(o) of the Disclosure Schedule and any individual who assumes or
performs any of the duties of a Key Employee.

     (p) Employee Relations. Neither the Company nor any of its Subsidiaries is involved
in any material union labor dispute nor, to the knowledge of the Company or any of its
Subsidiaries, is any such dispute threatened. The Company and its Subsidiaries believe that their
relations with their employees are good. No executive officer (as defined in Rule 501(f) of the
Securities Act) has notified the Company that such officer intends to leave the Company or
otherwise terminate such officer’s employment with the Company. The Company and its Subsidiaries
are in compliance with all federal, state, local and foreign laws and regulations respecting
employment and employment practices, terms and conditions of employment and wages and hours, except
where failure to be in compliance would not, either individually or in the aggregate, result in a
Material Adverse Effect.

- 11 -

 

     (q) Insurance. The Company and each of its Subsidiaries has in force fire, casualty,
product liability and other insurance policies, with extended coverage, sufficient in amount to
allow it to replace any of its material properties or assets which might be damaged or destroyed or
sufficient to cover liabilities to which the Company may reasonably become subject, and such types
and amounts of other insurance with respect to its business and properties, on both a per
occurrence and an aggregate basis, as are customarily carried by persons engaged in the same or
similar business as the Company. No default or event has occurred that could give rise to a
default under any such policy.

     (r) Environmental Matters. There is no environmental litigation or other
environmental proceeding pending or, to the knowledge of the Company or any of its Subsidiaries,
threatened by any governmental regulatory authority or others with respect to the current or any
former business of the Company or any of its Subsidiaries or any partnership or joint venture
currently or at any time affiliated with the Company or any of its Subsidiaries. No state of facts
exists as to environmental matters or Hazardous Substances (as defined below) that involves the
reasonable likelihood of a material capital expenditure by the Company or any of its Subsidiaries
that may otherwise have a Material Adverse Effect. To the Company’s knowledge, no Hazardous
Substances have been treated, stored or disposed of, or otherwise deposited, in or on the
properties owned or leased by the Company or any of its Subsidiaries or by any partnership or joint
venture currently or at any time affiliated with the Company or any of its Subsidiaries in
violation of any applicable environmental laws. The environmental compliance programs of the
Company and each of its Subsidiaries comply in all respects with all environmental laws, whether
foreign, federal, state, provincial or local, currently in effect. For purposes of this Agreement,
“Hazardous Substances” means any substance, waste, contaminant, pollutant or material that has been
determined by any governmental authority to be capable of posing a risk of injury to health,
safety, property or the environment.

     (s) Solvency. Based on the financial condition of the Company as of the Closing Date,
(i) the Company’s fair saleable value of its assets exceeds the amount that will be required to be
paid on or in respect of the Company’s existing debts and other liabilities (including known
contingent liabilities) as they mature; (ii) the Company’s assets do not constitute unreasonably
small capital to carry on its business for the current fiscal year as now conducted and as proposed
to be conducted including its capital needs taking into account the particular capital requirements
of the business conducted by the Company, and projected capital requirements and capital
availability thereof; and (iii) the current cash flow of the Company, together with the proceeds
the Company would receive, were it to liquidate all of its assets, after taking into account all
anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its debt
when such amounts are required to be paid. The Company does not intend to incur debts beyond its
ability to pay such debts as they mature (taking into account the timing and amounts of cash to be
payable on or in respect of its debt).

     (t) Listing. The Common Stock is currently listed for trading on the Nasdaq SmallCap
Market (the “SmallCap Market”). The Company is not in violation of the listing requirements of the
SmallCap Market and the Company does not presently reasonably anticipate that the Common Stock will
be delisted by the SmallCap Market during the one-year period immediately following the Closing.
The Company has not received any notice regarding the possible delisting of the Common Stock from
the SmallCap Market. On or prior to the Closing,

- 12 -

 

the Company will have secured the listing of the Underlying Common Shares on the SmallCap
Market and on each other national securities exchange, automated quotation system or
over-the-counter market upon which shares of Common Stock are currently listed (subject to official
notice of issuance).

     (u) Form S-3 Eligibility. The Company is eligible to register the resale of its
Common Stock on a registration statement on Form S-3 under the Securities Act. There exist no
facts or circumstances that would prohibit or delay the preparation and filing of a registration
statement on Form S-3 with respect to the Registrable Securities (as defined in the Registration
Rights Agreement). The Company has no basis to believe that its past or present independent public
auditors will withhold their consent to the inclusion, or incorporation by reference, of their
audit opinion concerning the Company’s financial statements which are included in the Registration
Statement required to be filed pursuant to the Registration Rights Agreement.

     (v) Anti-Takeover Provisions. The Company and its board of directors have taken all
necessary action, if any, in order to render inapplicable any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement) or other similar
anti-takeover provision under its Certificate of Incorporation or the laws of the state of its
incorporation which is or could become applicable to the Purchaser as a result of the transactions
contemplated by this Agreement, including, without limitation, the Company’s issuance of the
Securities and any and all Purchaser’s ownership of the Securities.

     (w) Acknowledgment Regarding The Purchaser’s Purchase of the Securities. The Company
acknowledges and agrees that the Purchaser is acting solely in the capacity of arm’s length
purchaser with respect to this Agreement and the other Transaction Documents and the transactions
contemplated hereby and thereby, and that, as of the date of this Agreement and as of Closing, the
Purchaser is not (i) an officer or director of the Company, or (ii) an “affiliate” of the Company
(as defined in Rule 144 under the Securities Act (including any successor rule, “Rule 144”)). The
Company further acknowledges that the Purchaser is not acting as a financial advisor or fiduciary
of the Company (or in any similar capacity) with respect to this Agreement or the other Transaction
Documents and the transactions contemplated hereby and thereby, and any advice given by a Purchaser
or any of its representatives or agents in connection with this Agreement or the other Transaction
Documents and the transactions contemplated hereby and thereby is merely incidental to the
Purchaser’s purchase of the Securities. The Company further represents to the Purchaser that the
Company’s decision to enter into this Agreement and the other Transaction Documents has been based
solely on the independent evaluation by the Company and its representatives.

     (x) No General Solicitation or Integrated Offering. Neither the Company nor any
distributor participating on the Company’s behalf in the transactions contemplated hereby (if any)
nor any person acting for the Company, or any such distributor, has conducted any “general
solicitation” (as such term is defined in Regulation D) with respect to any of the Securities being
offered hereby. Neither the Company nor any of its affiliates, nor any person acting on its or
their behalf, has directly or indirectly made any offers or sales of any security or solicited any
offers to buy any security under circumstances that would require registration of the Securities
being offered hereby under the Securities Act or cause this offering of Securities to be integrated
with any prior offering of securities of the Company for purposes of the Securities Act, which

- 13 -

 

result of such integration would require registration under the Securities Act, or any
applicable stockholder approval provisions.

     (y) No Brokers. Other than the consulting fee to Saffron Capital Management LLC
referred to in Section 4(q), the Company has taken no action that would give rise to any claim by
any person for brokerage commissions, finder’s fees or similar payments by any Purchaser relating
to this Agreement or the transactions contemplated hereby.

     (z) Acknowledgment Regarding Securities. The number of Conversion Shares issuable
upon conversion of the Series B Preferred Stock and the number of Warrant Shares issuable upon
exercise of the Warrants may increase in certain circumstances. The Company’s directors and
executive officers have studied and fully understand the nature of the Securities being sold
hereunder. The Company acknowledges that its obligation to issue Conversion Shares upon conversion
of the Series B Preferred Stock in accordance with the terms thereof and the Warrant Shares upon
the exercise of the Warrants in accordance with the terms thereof is absolute and unconditional,
regardless of the dilution that such issuance may have on the ownership interests of other
stockholders and the availability of remedies provided for in any of the Transaction Documents
relating to a failure or refusal to issue any Underlying Common Shares. Taking the foregoing into
account, the Company’s Board of Directors has determined in its good faith business judgment that
the issuance of the Securities hereunder and the consummation of the other transactions
contemplated hereby are in the best interests of the Company and its stockholders.

     (aa) Disclosure. All information relating to or concerning the Company and/or any of
its Subsidiaries set forth in this Agreement or provided to the Purchaser pursuant to Section 2(d)
hereof or otherwise in connection with the transactions contemplated hereby is true and correct in
all material respects and the Company has not omitted to state any material fact necessary in order
to make the statements made herein or therein, in light of the circumstances under which they were
made, not misleading. No event or circumstance has occurred or exists with respect to the Company
or its Subsidiaries or their respective businesses, properties, prospects, operations or financial
conditions, which has not been publicly disclosed but, under applicable law, rule or regulation,
would be required to be disclosed by the Company in an annual or quarterly report filed on the date
hereof by the Company under the Exchange Act.

	4.	 	COVENANTS.

     (a) Commercially Reasonable Efforts. The parties shall use their respective
commercially reasonable efforts timely to satisfy each of the conditions described in Sections 6
and 7 of this Agreement.

     (b) Form D; Blue Sky Laws. The Company shall file with the SEC a Form D with respect
to the Securities as required under Regulation D and provide a copy thereof to the Purchaser
promptly after such filing. The Company shall, on or before the Closing Date, take such action as
the Company shall reasonably determine is necessary to qualify the Securities for sale to the
Purchaser pursuant to this Agreement under applicable securities or “blue sky” laws of the states
of the United States or obtain exemption therefrom, and shall provide evidence of any such action
so taken to the Purchaser on or prior to the Closing Date. Before the beginning

- 14 -

 

of the trading day immediately following the Closing Date, the Company shall file a Form 8-K
with the SEC concerning this Agreement and the transactions contemplated hereby, which Form 8-K
shall attach this Agreement and its Exhibits as exhibits to such Form 8-K (the “8-K Filing”). As
of the date of the 8-K Filing, the Company hereby acknowledges that no Purchaser shall be in
possession of any material nonpublic information received from the Company, any of its Subsidiaries
or any of its respective officers, directors, employees or agents, that is not disclosed in the 8-K
Filing. The Company shall not, and shall cause each of its Subsidiaries and its and each of their
respective officers, directors, employees and agents not to, provide any Purchaser with any
material nonpublic information regarding the Company or any of its Subsidiaries from and after the
8-K Filing without the express written consent of the Purchaser; provided, however, that a
Purchaser that exercises its rights under Section 4(m) hereof or Article XI.B, XI.C or XI.D of the
Series B Certificate of Designation shall be deemed to have given such express written consent, but
only with respect to the information obtained as a direct result of the assertion of such rights.
Subject to the foregoing, neither the Company nor any Purchaser shall issue any press releases or
any other public statements with respect to the transactions contemplated hereby; provided,
however, that the Company shall be entitled, without the prior approval of any Purchaser, to make
any press release or other public disclosure with respect to such transactions (i) in substantial
conformity with the 8-K Filing and contemporaneously therewith and (ii) as is required by
applicable law and regulations (provided that in the case of clause (i) the Purchaser shall be
consulted by the Company in connection with any such press release or other public disclosure prior
to its release).

     (c) Reporting Status. So long as the Purchaser (or any of their respective
affiliates) beneficially owns any of the Securities, the Company shall timely file all reports
required to be filed with the SEC pursuant to the Exchange Act, and the Company shall not terminate
its status as an issuer that files reports under the Exchange Act even if the Exchange Act or the
rules and regulations thereunder would permit such termination. In addition, the Company shall
take all actions necessary to meet the “registrant eligibility” requirements set forth in the
general instructions to Form S-3 or any successor form thereto, to continue to be eligible to
register the resale of its Common Stock on a registration statement on Form S-3 under the
Securities Act.

     (d) Use of Proceeds. The Company shall use the proceeds from the sale and issuance of
the Securities for general corporate purposes and working capital. Such proceeds shall not be used
to (i) pay dividends; (ii) pay for any increase in executive compensation, pay any severance fee or
similar payment, or make any loan or other advance to any officer, employee, shareholder, director
or other affiliate of the Company, without the express approval of the Board of Directors acting in
accordance with past practice; (iii) purchase debt or equity securities of any entity (including
redeeming the Company’s own securities), except for (A) evidences of indebtedness issued or fully
guaranteed by the United States of America and having a maturity of not more than one year from the
date of acquisition, (B) certificates of deposit, notes, acceptances and repurchase agreements
having a maturity of not more than one year from the date of acquisition issued by a bank organized
in the United States having capital, surplus and undivided profits of at least $500,000,000, (C)
the highest-rated commercial paper having a maturity of not more than one year from the date of
acquisition, and (D) “Money Market” fund shares, or money market accounts fully insured by the
Federal Deposit Insurance Corporation and sponsored by banks and other financial institutions,
provided that the investments consist principally of the types of investments described in clauses
(A), (B), or (C) above; (iv) make any investment not directly

- 15 -

 

related to the current business of the Company; or (v) to satisfy any obligations pursuant to
the Plan of Reorganization, including the payment of any Claims (as defined therein) pursuant
thereto.

     (e) Financial Information. So long as the Purchaser (or any of its respective
affiliates) beneficially owns any of the Securities, the Company shall send (via electronic
transmission or otherwise) the following reports to each the Purchaser: (i) within ten days after
the filing with the SEC, a copy of its Annual Report on Form 10-K, its Quarterly Reports on Form
10-Q, its proxy statements and any Current Reports on Form 8-K; and (ii) within one day after
release, copies of all press releases issued by the Company or any of its Subsidiaries.

     (f) Reservation of Shares. The Company currently has authorized and reserved for the
purpose of issuance 10,000,000 shares of Common Stock to provide for the full conversion of the
Series B Preferred Stock and issuance of the Conversion Shares in connection therewith, the
exercise of the Warrants and the issuance of the Warrant Shares in connection therewith and as
otherwise required by the Series B Certificate of Designation, the Warrants, the Note and the
Registration Rights Agreement (collectively, the “Issuance Obligations”). In the event such number
of shares becomes insufficient to satisfy the Issuance Obligations, the Company shall take all
necessary action to authorize and reserve such additional shares of Common Stock necessary to
satisfy the Issuance Obligations.

     (g) Listing. So long as the Purchaser (or any of its affiliates) beneficially owns
any of the Securities, the Company shall maintain the listing of all Underlying Common Shares from
time to time issuable upon conversion of the Series B Preferred Stock and upon exercise of the
Warrants on each national securities exchange, automated quotation system or electronic bulletin
board on which shares of Common Stock are currently listed. The Company shall use commercially
reasonable efforts to continue the listing and trading of its Common Stock on the SmallCap Market
or on the Nasdaq National Market (the “National Market”), the New York Stock Exchange (the “NYSE”)
or the American Stock Exchange (the “AMEX”) and shall comply in all respects with the reporting,
filing and other obligations under the bylaws or rules of the National Association of Securities
Dealers, Inc. (the “NASD”), such exchanges, or such electronic system, as applicable. The Company
shall promptly provide to the Purchaser copies of any notices it receives regarding the continued
eligibility of the Common Stock for trading on any securities exchange or automated quotation
system on which securities of the same class or series issued by the Company are then listed or
quoted, if any.

     (h) Corporate Existence. So long as the Purchaser (or any of its affiliates)
beneficially owns any of the Securities, the Company shall maintain its corporate existence, and in
the event of a merger, consolidation or sale of all or substantially all of the Company’s assets,
the Company shall ensure that the surviving or successor entity in such transaction (i) assumes the
Company’s obligations under this Agreement and the other Transaction Documents and the agreements
and instruments entered into in connection herewith and therewith regardless of whether or not the
Company would have had a sufficient number of shares of Common Stock authorized and available for
issuance in order to effect the conversion of all the Series B Preferred Stock and exercise in full
of all Warrants outstanding as of the date of such transaction and (ii) except in the event of a
merger, consolidation of the Company into any other corporation, or the sale or conveyance of all
or substantially all of the assets of the Company

- 16 -

 

where the consideration consists solely of cash, the surviving or successor entity is a
publicly traded corporation whose common stock is listed for trading on the SmallCap Market, the
National Market, the NYSE or the AMEX.

     (i) No Integrated Offerings. The Company shall not make any offers or sales of any
security (other than the Securities) under circumstances that would require registration of the
Securities being offered or sold hereunder under the Securities Act or cause this offering of the
Securities to be integrated with any other offering of securities by the Company.

     (j) Legal Compliance. The Company shall conduct its business and the business of its
Subsidiaries in compliance with all laws, ordinances or regulations of governmental entities
applicable to such businesses, except where the failure to do so would not have a Material Adverse
Effect.

     (k) Redemptions, Dividends and Repayments of Indebtedness. Except as contemplated
hereby, so long as the Purchaser (or any of its affiliates) beneficially owns any of the Series B
Preferred Stock, the Company shall not, without first obtaining the written approval of the holders
of a majority of the shares of Series B Preferred Stock then outstanding (which approval may be
given or withheld by such holders in their sole and absolute discretion), repurchase, redeem or
declare or pay any cash dividend or distribution on any shares of capital stock of the Company or
repay or prepay any indebtedness of the Company other than as expressly required pursuant to the
terms of such indebtedness as in effect on the date hereof.

     (l) Information. So long as the Purchaser (or any of its affiliates) beneficially
owns any of the Securities, the Company shall furnish to the Purchaser:

          (i) concurrently with the filing with the SEC of its annual reports on Form 10-K, a
certificate of the President, a Vice President or a senior financial officer of the Company stating
that, based upon such examination or investigation and review of this Agreement as in the opinion
of the signer is necessary to enable the signer to express an informed opinion with respect
thereto, neither the Company nor any of its Subsidiaries is or has during such period been in
default in the performance or observance of any of the terms, covenants or conditions hereof, or,
if the Company or any of its Subsidiaries shall be or shall have been in default, specifying all
such defaults, and the nature and period of existence thereof, and what action the Company or such
Subsidiary has taken, is taking or proposes to take with respect thereto; and

          (ii) the information the Company must deliver to any holder or to any prospective transferee
of Securities in order to permit the sale or other transfer of such Securities pursuant to Rule
144A of the SEC or any similar rule then in effect.

The Company shall keep at its principal executive office a true copy of this Agreement (as at the
time in effect), and cause the same to be available for inspection at such office during normal
business hours by any holder of Securities or any prospective transferee of Securities designated
by a holder thereof.

     (m) Inspection of Properties and Books. So long as the Purchaser (or any of its
affiliates) beneficially owns any of the Securities, each the Purchaser who then holds Securities

- 17 -

 

and its representatives and agents (collectively, the “Inspectors”) shall have the right, at
the Purchaser’s expense, to visit and inspect any of the properties of the Company and of its
Subsidiaries, to examine the books of account and records of the Company and of its Subsidiaries,
to make or be provided with copies and extracts therefrom, to discuss the affairs, finances and
accounts of the Company and of its Subsidiaries with, and to be advised as to the same by, its and
their officers, employees and independent public accountants (and by this provision the Company
authorizes such accountants to discuss such affairs, finances and accounts, whether or not a
representative of the Company is present) all at such reasonable times and intervals and to such
reasonable extent as the Purchaser may desire; provided, however, that each Inspector shall hold in
confidence and shall not make any disclosure (except to the Purchaser) of any such information
which the Company determines in good faith to be confidential, and of which determination the
Inspectors are so notified, unless (i) the disclosure of such information is necessary to avoid or
correct a misstatement or omission in any Registration Statement filed pursuant to the Registration
Rights Agreement (in which case the Company shall immediately promptly (but in no event more than
two trading days after receiving notification from the Inspector) a Form 8-K with the SEC
disclosing such information), (ii) the release of such information is ordered pursuant to a
subpoena or other order from a court or government body of competent jurisdiction, or (iii) such
information has been made generally available to the public other than by disclosure in violation
of this or any other agreement. The Purchaser agrees that it shall, upon learning that disclosure
of such information is sought in or by a court or governmental body of competent jurisdiction or
through other means, give prompt notice to the Company and allow the Company, at its expense, to
undertake appropriate action to prevent disclosure of, or to obtain a protective order for, the
information deemed confidential.

     (n) Shareholders Rights Plan. No claim shall be made or enforced by the Company or
any director, officer, employee, representative or other person acting on behalf of the Company
that any Purchaser is an “Acquiring Person” under any shareholders rights plan or similar plan or
arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to
trigger the provisions of any such plan or arrangement, by virtue of receiving Securities under
this Agreement or any other Transaction Documents or under any other agreement between the Company
and the Purchaser.

     (o) Pledge of Securities. The Company acknowledges and agrees that the Securities may
be pledged by any Purchaser in connection with a bona fide margin agreement or other loan or
financing arrangement that is secured by the Securities. The pledge of Securities shall not be
deemed to be a transfer, sale or assignment of the Securities hereunder, and no Purchaser effecting
a pledge of Securities shall be required to provide the Company with any notice thereof or
otherwise make any delivery to the Company pursuant to this Agreement or any other Transaction
Document. The Company shall execute and deliver such documentation as a pledgee of the Securities
may reasonably request in connection with a pledge of the Securities to such pledgee by a
Purchaser.

     (p) Variable Securities. So long as the Purchaser (or any of their respective
affiliates) beneficially owns any of the Securities, the Company shall not, without first obtaining
the written approval of the holders of a majority of the shares of Series B Preferred Stock then
outstanding (which approval may be given or withheld by such holders in their sole and absolute
discretion), issue or sell any rights, warrants or options to subscribe for or purchase Common

- 18 -

 

Stock, or any other securities directly or indirectly convertible into or exchangeable or
exercisable for Common Stock, at an effective conversion, exchange or exercise price that varies or
may vary with the market price of the Common Stock, including by way of one or more reset(s) to any
fixed price.

     (q) Expenses. At the Closing, the Company shall pay to the Purchaser reimbursement
for the out-of-pocket expenses reasonably incurred by the Purchaser, its affiliates and its
advisors in connection with the negotiation, preparation, execution and delivery of this Agreement
and the other Transaction Documents and the consummation of the transactions contemplated hereby
and thereby, including, without limitation, the Purchaser’s and their respective affiliates’ and
advisors’ reasonable due diligence and attorneys’ fees and expenses (the “Expenses”); provided,
however, that the Purchaser shall be permitted, in its discretion, to deduct all of its Expenses
from the aggregate purchase price payable by the Purchaser hereunder; and provided, further, that
the aggregate amount of the Expenses payable to the Purchaser shall not exceed $110,000.00 (the
“Expense Cap”). The Company shall pay the Purchaser fifty thousand dollars ($50,000) of this
Expense Cap concurrently with the execution of this Agreement. In addition, from time to time
thereafter, upon any Purchaser’s written request, the Company shall pay to the Purchaser such
additional Expenses (not to exceed in the aggregate the Expense Cap), if any, not covered by such
payment, in each case to the extent reasonably incurred by the Purchaser, its affiliates or its or
their advisors in connection with the negotiation, preparation, execution and delivery of this
Agreement and the other Transaction Documents and the consummation of the transactions contemplated
hereby and thereby. In addition to the foregoing, the Company shall pay Saffron Capital Management
LLC a consulting fee in the amount of $125,000 which SDS Capital Group SPC, Ltd. shall be entitled
to deduct from the purchase price payable by it hereunder and pay directly to Saffron Capital
Management LLC.

     (r) Right of First Refusal. If the Company desires to contract with or otherwise
engage any unrelated third party to provide technical recruiting, call center service, outsourced
software engineering and integration services, or any similar services (collectively, the
“Outsourced Services”), the Company shall give written notification (the “Outsourcing
Notification”) of such desire to SDS Capital Group SPC, Ltd. SDS Capital Group SPC, Ltd. shall
have fifteen (15) days from its receipt of the Outsourcing Notification in which to advise the
Company of its desire to appoint a designee (the “Outsourcing Designee”) to provide such Outsourced
Services to the Company. The Outsourcing Designee shall then have the exclusive right, during the
thirty (30) day period following the date on which the Company receives written notice of such
Outsourcing Designee’s appointment, to develop and deliver to the Company a formal proposal (the
“Proposal”) for the provision of such Outsourced Services. The Company shall accept such Proposal
if the terms of the Proposal are commercially reasonable. If an Outsourcing Designee is not
appointed, or if the Outsourcing Designee fails to deliver to the Company a Proposal in the manner
described above, the Company shall have the right to solicit and consider alternative proposals to
provide such Outsourced Services, provided, however, that if a contract to provide such Outsourced
Services is not executed within ninety (90) days after the Outsourcing Notification, then the
provisions of this Section 4(s) will apply again to the Outsourced Services as if the initial
Outsourcing Notification had ever been provided.

     (s) Investment Oversight Committee. Effective as of the date hereof, an investment
oversight committee (the “Investment Oversight Committee”) shall be established for the

- 19 -

 

purpose of monitoring the disbursement of the net proceeds to the Corporation (i) in
connection with the Note issuance and (ii) from the issuance and sale of the Series B Preferred
Stock. The Investment Oversight Committee shall consist of two (2) members. The initial members
shall be W. Michael Smith and Raahim Don. All expenditures of the proceeds resulting from the
sales of securities by the Corporation pursuant to the Series B Securities Purchase Agreement shall
require the unanimous, prior, written approval of the members of the Investment Oversight
Committee. The Investment Oversight Committee shall remain in existence until the Company has used
all of the proceeds received in connection with the transactions contemplated by this Agreement.

     (t) Stockholder Approval. Promptly following the date hereof , the Company and its
Board of Directors shall (i) prepare proxy materials and solicit proxies requesting Stockholder
Approval (as defined below), (ii) call an annual or special meeting (the “Special Meeting”) of the
Company’s stockholders (which shall be held no later than August 1, 2005, subject to any delay
caused solely by the SEC’s review of the preliminary proxy statement relating thereto or clearance
of the materials under applicable SEC rules and regulations) for the purpose of obtaining
Stockholder Approval, (iii) recommend that the Company’s stockholders vote in favor of such
approval, and (iv) otherwise use commercially reasonable best efforts to obtain Stockholder
Approval. If Stockholder Approval is not obtained at the Special Meeting, the Company and its
Board of Directors shall continue to use commercially reasonable best efforts to obtain Stockholder
Approval until Stockholder Approval is obtained. A request for Stockholder Approval, unless the
Board of Directors receives an opinion of counsel advising that such recommendation would
constitute a breach of the directors’ fiduciary duties imposed by applicable law, shall include a
recommendation that the Company’s stockholders vote in favor of such approval. All expenses
related to the solicitation of proxies with respect to, or otherwise incurred in connection with,
obtaining Stockholder Approval shall be borne by the Company. “Stockholder Approval” means the
affirmative vote by the holders of the requisite number of votes cast at a meeting of stockholders
to duly and validly approve (i) the issuance of the Exchange Warrants upon exchange of the Note in
accordance with the terms and conditions thereof and of this Agreement, (ii) the issuance of the
Series B Preferred Stock and the C-3 Warrant pursuant to this Agreement, in the event that Nasdaq
requires stockholder approval of these transactions in connection with the Supplemental Listing
Application (as described in Section 4(u) below), and (iii) any other transaction contemplated
hereby which respect to which Nasdaq requires specific stockholder approval in connection with the
Supplemental Listing Application (as described in Section 4(u) below).

     (u) Nasdaq Review. Promptly following the execution of this Agreement, the Purchaser
and the Company shall cooperate to (i) submit to the Listing Department a copy of this Agreement
and any ancillary Transaction Documents that the parties shall agree upon, for, (ii) request that
the Listing Department review the Agreement and any other submitted documents and, following such
review, approve the Company’s Supplemental Listing Application (provided, however, that the Company
shall clarify to Nasdaq in connection with such Supplemental Listing Application that the Company
does not intend to seek Stockholder Approval of the sale and issuance of the Series B Preferred
Stock or the C-3 Warrant), and (iii) respond to any requests from the Listing Department for
further information or documentation, or to discuss any matters relating to this Agreement and the
transactions contemplated hereby.

- 20 -

 

     (v) Operation of Business. Except as otherwise contemplated by this Agreement, during
the period from the date hereof to the Closing Date, the Company shall conduct its business in the
ordinary course of business and use commercially reasonable efforts to preserve intact in all
material respects the business organization of the business, keep available the services of its
officers and employees, and maintain its present relationships with licensors, suppliers,
distributors, customers and others having significant business relationships with it.

	5.	 	SECURITIES TRANSFER MATTERS.

     (a) Conversion and Exercise. Upon conversion of the Series B Preferred Stock or
exercise of the Warrants by any person, (i) if the DTC Transfer Conditions (as defined below) are
satisfied, the Company shall cause its transfer agent to electronically transmit all Underlying
Common Shares by crediting the account of such person or its nominee with the Depository Trust
Company (“DTC”) through its Deposit Withdrawal Agent Commission system; or (ii) if the DTC Transfer
Conditions are not satisfied, the Company shall issue and deliver, or instruct its transfer agent
to issue and deliver, certificates (subject to the legend and other applicable provisions hereof
and the Series B Certificate of Designation and Warrants), registered in the name of such person
its nominee, physical certificates representing the Underlying Common Shares, as applicable. Even
if the DTC Transfer Conditions are satisfied, any person effecting a conversion of Series B
Preferred Stock or exercising Warrants may instruct the Company to deliver to such person or its
nominee physical certificates representing the Underlying Common Shares, as applicable, in lieu of
delivering such shares by way of DTC Transfer. For purposes of this Agreement, “DTC Transfer
Conditions” means that (A) the Company’s transfer agent is participating in the DTC Fast Automated
Securities Transfer program and (B) the certificates for the Underlying Common Shares required to
be delivered do not bear a legend and the person effecting such conversion or exercise is not then
required to return such certificate for the placement of a legend thereon.

     (b) Transfer or Resale. The Purchaser understands that (i) except as provided in the
Registration Rights Agreement, the sale or resale of the Securities have not been and are not being
registered under the Securities Act or any state securities laws, and the Securities may not be
transferred unless (A) the transfer is made pursuant to and as set forth in an effective
registration statement under the Securities Act covering the Securities; or (B) the Purchaser shall
have delivered to the Company an opinion of counsel (which opinion shall be in form, substance and
scope customary for opinions of counsel in comparable transactions) to the effect that the
Securities to be sold or transferred may be sold or transferred pursuant to an exemption from such
registration under the Securities Act or any state securities laws; or (C) sold under and in
compliance with Rule 144; and (ii) neither the Company nor any other person is under any obligation
to register such Securities under the Securities Act or any state securities laws (other than
pursuant to the terms of the Registration Rights Agreement). Notwithstanding the foregoing or
anything else contained herein to the contrary, the Securities may be pledged as collateral in
connection with a bona fide margin account or other lending arrangement, provided such pledge is
consistent with applicable laws, rules and regulations.

     (c) Legends. The Purchaser understands that the Series B Preferred Stock, the Note
and the Warrants and, until such time as the Underlying Common Shares have been registered

- 21 -

 

under the Securities Act (including registration pursuant to Rule 416 thereunder) as
contemplated by the Registration Rights Agreement or otherwise may be sold by the Purchaser under
Rule 144, the certificates for the Underlying Common Shares may bear a restrictive legend in
substantially the following form:

The securities represented by this certificate have not been
registered under the Securities Act of 1933, as amended, or the
securities laws of any state of the United States or in any other
jurisdiction. The securities represented hereby may not be offered,
sold or transferred in the absence of an effective registration
statement for the securities under applicable securities laws unless
offered, sold or transferred pursuant to an available exemption from
the registration requirements of those laws.

     The Company shall, immediately prior to a registration statement covering the Securities
(including, without limitation, the Registration Statement contemplated by the Registration Rights
Agreement) being declared effective, deliver to its transfer agent an opinion letter of counsel,
opining that at any time such registration statement is effective, the transfer agent shall issue,
in connection with the issuance of the Underlying Common Shares, certificates representing such
Underlying Common Shares without the restrictive legend above, provided such Underlying Common
Shares are to be sold pursuant to the prospectus contained in such registration statement. Upon
receipt of such opinion, the Company shall use commercially reasonable efforts to cause the
transfer agent to confirm, for the benefit of the holders, that no further opinion of counsel is
required at the time of transfer in order to issue such shares without such restrictive legend.

     The legend set forth above shall be removed and the Company shall issue a certificate without
such legend to the holder of any Security upon which it is stamped, if, unless otherwise required
by state securities laws, (i) the sale of such Security is registered under the Securities Act
(including registration pursuant to Rule 416 thereunder); (ii) such holder provides the Company
with an opinion of counsel, in form, substance and scope customary for opinions of counsel in
comparable transactions, to the effect that a public sale or transfer of such Security may be made
without registration under the Securities Act; or (iii) such holder provides the Company with
reasonable assurances that such Security can be sold under Rule 144. In the event the above legend
is removed from any Security and thereafter the effectiveness of a registration statement covering
such Security is suspended or the Company determines that a supplement or amendment thereto is
required by applicable securities laws, then upon reasonable advance written notice to the
Purchaser the Company may require that the above legend be placed on any such Security that cannot
then be sold pursuant to an effective registration statement or under Rule 144 and the Purchaser
shall cooperate in the replacement of such legend. Such legend shall thereafter be removed when
such Security may again be sold pursuant to an effective registration statement or under Rule 144.

     (d) Transfer Agent Instruction. Upon compliance by any Purchaser with the provisions
of this Section 5 with respect to the transfer of any Securities, the Company shall permit the
transfer of such Securities and, in the case of the transfer of Conversion Shares or Warrant
Shares, promptly instruct its transfer agent to issue one or more certificates (or effect a

- 22 -

 

DTC Transfer) in such name and in such denominations as specified by the Purchaser. The
Company shall not give any instructions to its transfer agent with respect to the Securities, other
than any permissible or required instructions provided in this Section 5, and the Securities shall
otherwise be freely transferable on the books and records of the Company as and to the extent
provided in this Agreement.

	6.	 	CONDITIONS TO THE COMPANY’S OBLIGATIONS TO ISSUE SECURITIES AT THE CLOSINGS.

     (a) Conditions to Both Closings. The obligation of the Company hereunder to issue and
sell the Series B Preferred Stock and C-3 Warrant to the Purchaser hereunder is subject to the
satisfaction, at or before the Series B Closing Date, and the obligation of the Company hereunder
to issue and sell the C-1 Warrant and C-2 Warrant to the Purchaser hereunder is subject to the
satisfaction, at or before the Exchange Closing Date, of each of the following conditions, provided
that such conditions are for the Company’s sole benefit and may be waived by the Company at any
time in its sole discretion:

          (i) Bridge Loan. The parties hereto shall have consummated the loan and issuance of
the Note contemplated in Section 1(a) hereof.

          (ii) Execution of Transaction Documents. The Purchaser shall have executed the
Purchaser’s Execution Page to this Agreement and each other Transaction Document to which the
Purchaser is a party and delivered the same to the Company.

          (iii) Nasdaq Approval. The Nasdaq Stock Market, Inc. Listing Qualifications
Department (the “Listing Department”) shall have advised the Company of the Listing Department’s
approval of the Company’s Supplemental Listing Application, subject to stockholder approval of the
issuance of the C-1 Warrant and the C-2 Warrant in connection with the Exchange.

          (iv) Representations and Warranties True; Covenants Performed. The representations
and warranties of the Purchaser shall be true and correct in all material respects as of the date
when made and as of such Closing Date as though made at that time (except for representations and
warranties that speak as of a specific date, which representations and warranties shall be true and
correct as of such date), and the Purchaser shall have performed, satisfied and complied with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or
complied with by the Purchaser at or prior to such Closing Date.

          (v) No Legal Prohibition. No statute, rule, regulation, executive order, decree,
ruling, injunction, action or proceeding shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction or any self-regulatory
organization having authority over the matters contemplated hereby which restricts or prohibits the
consummation of any of the transactions contemplated by this Agreement.

     (b) Additional Conditions to Series B Closing. The obligation of the Company
hereunder to issue and sell the Series B Preferred Stock and C-3 Warrant to the Purchaser hereunder
is subject to the satisfaction, at or before the Series B Closing Date, of each of the

- 23 -

 

following additional conditions, provided that such conditions are for the Company’s sole
benefit and may be waived by the Company at any time in its sole discretion:

          (i) Stockholder Approval. The Company shall have obtained Stockholder Approval with
respect to the sale and issuance of the Series B Preferred Stock and C-3 Warrant, if Nasdaq
requires such Stockholder Approval as a condition to the sale and issuance of the Series B
Preferred Stock and C-3 Warrant (as described in Section 4(u) hereof).

          (ii) Payment of Purchase Price. The Purchaser shall have delivered the full amount of
the Series B Purchase Price to the Company by wire transfer in accordance with the Company’s
written wiring instructions.

     (c) Additional Conditions to Exchange Closing. The obligation of the Company
hereunder to issue and sell the C-1 Warrant and C-2 Warrant to the Purchaser hereunder is subject
to the satisfaction, at or before the Exchange Closing Date, of each of the following conditions,
provided that such conditions are for the Company’s sole benefit and may be waived by the Company
at any time in its sole discretion:

          (i) Stockholder Approval. The Company shall have obtained Stockholder Approval with
respect to the sale and issuance of the C-1 Warrant and the C-2 Warrant.

          (ii) The Purchaser shall surrendered the Note to the Company for exchange pursuant to the
terms thereof.

	7.	 	CONDITIONS TO THE PURCHASER’S OBLIGATIONS TO PURCHASE SECURITIES AT THE CLOSINGS.

     (a) Conditions to Both Closings. The obligation of the Purchaser to exchange the
Series A Preferred Stock and pay cash to purchase the Series B Preferred Stock and C-3 Warrant
hereunder is subject to the satisfaction, at or before the Series B Closing Date, and the
obligation of the Purchaser to exchange the Note for the C-1 Warrant and C-2 Warrant hereunder is
subject to the satisfaction, at or before the Exchange Closing Date, of each of the following
conditions, provided that such conditions are for the Purchaser’s sole benefit and may be waived by
the Purchaser at any time in its sole discretion:

          (i) Bridge Loan. The parties hereto shall have consummated the loan and issuance of
the Note contemplated in Section 1(a) hereof.

          (ii) Execution of Transaction Documents. The Company shall have executed the
Company’s Execution Page to this Agreement and each other Transaction Document to which the Company
is a party (other than the Warrants) and delivered executed originals of the same to the Purchaser.

          (iii) Nasdaq Approval. The Listing Department shall have advised the Company of the
Listing Department’s approval of the Company’s Supplemental Listing Application, subject to
stockholder approval of the issuance of the C-1 Warrant and the C-2 Warrant in connection with the
Exchange.

- 24 -

 

          (iv) Filing of Certificate of Designation. The Certificate of Designation shall have
been filed and accepted for filing with the Secretary of State of the State of Delaware and a copy
thereof certified by the Secretary of State of the State of Delaware shall have been delivered to
the Purchaser.

          (v) Listing. The Common Stock shall be authorized for quotation and listed on the
SmallCap Market and trading in the Common Stock (or on the SmallCap Market generally) shall not
have been suspended by the SEC or the SmallCap Market.

          (vi) Representations and Warranties True; Covenants Performed. The representations
and warranties of the Company, to the extent qualified by materiality or Material Adverse Effect,
shall be true and correct as of the date when made and as of the Closing Date as though made at
that time (except for representations and warranties that speak as of a specific date, which
representations and warranties shall be true and correct as of such date); the representations and
warranties of the Company, to the extent not qualified by materiality or Material Adverse Effect,
shall be true and correct in all material respects as of the date when made and as of the Closing
Date as though made at that time (except for representations and warranties that speak as of a
specific date, which representations and warranties shall be true and correct in all material
respects as of such date); and the Company shall have performed, satisfied and complied with the
covenants, agreements and conditions required by this Agreement to be performed, satisfied or
complied with by the Company at or prior to the Closing Date. The Purchaser shall have received a
certificate, executed by the Chief Executive Officer of the Company after reasonable investigation,
dated as of the Closing Date, to the foregoing effect and as to such other matters as may
reasonably be requested by the Purchaser.

          (vii) No Legal Prohibition. No statute, rule, regulation, executive order, decree,
ruling, injunction, action or proceeding shall have been enacted, entered, promulgated or endorsed
by any court or governmental authority of competent jurisdiction or any self-regulatory
organization having authority over the matters contemplated hereby which restricts or prohibits the
consummation of, any of the transactions contemplated by this Agreement.

          (viii) Legal Opinion. The Purchaser shall have received an opinion of the Company’s
counsel, dated as of the Closing Date, in the substantially the same form as the legal opinion of
Company’s counsel delivered to the Purchaser in connection with the sale and issuance of the Series
A Preferred Stock to the Purchaser.

          (ix) No Material Adverse Change. There shall have been no material adverse changes
and no material adverse developments in the business, properties, operations, prospects, financial
condition or results of operations of the Company and its Subsidiaries, taken as a whole, since the
date hereof.

          (x) Corporate Approvals. The Purchaser shall have received a copy of resolutions,
duly adopted by the Board of Directors of the Company, which shall be in full force and effect at
the time of the Closing, authorizing the execution, delivery and performance by the Company of this
Agreement and the other Transaction Documents and the consummation by the Company of the
transactions contemplated hereby and thereby, certified as such by the Secretary

- 25 -

 

or Assistant Secretary of the Company, and such other documents they reasonably request in
connection with the Closing.

     (b) Additional Conditions to Series B Closing. The obligation of the Purchaser
hereunder to exchange the Series A Preferred Stock and pay cash to purchase the Series B Preferred
Stock and C-3 Warrant is subject to the satisfaction, at or before the Series B Closing Date, of
each of the following additional conditions, provided that such conditions are for the Purchaser’s
sole benefit and may be waived by the Purchaser at any time in its sole discretion:

          (i) Stockholder Approval. The Company shall have obtained Stockholder Approval with
respect to the sale and issuance of the Series B Preferred Stock and C-3 Warrant, if Nasdaq
requires such Stockholder Approval as a condition to the sale and issuance of the Series B
Preferred Stock and C-3 Warrant (as described in Section 4(u) hereof).

          (ii) Delivery of Securities. The Company shall have delivered to the Purchaser (i)
duly executed certificates representing the Series B Preferred Stock and (ii) the duly executed C-3
Warrant (each in proper form and in such denominations as the Purchaser shall reasonably request),
registered in the Purchaser’s name.

     (c) Additional Conditions to Exchange Closing. The obligation of the Company
hereunder to exchange the Note for the C-1 Warrant and C-2 Warrant hereunder is subject to the
satisfaction, at or before the Exchange Closing Date, of each of the following additional
conditions, provided that such conditions are for the Purchaser’s sole benefit and may be waived by
the Purchaser at any time in its sole discretion:

          (i) Stockholder Approval. The Company shall have obtained Stockholder Approval with
respect to the sale and issuance of the C-1 Warrant and the C-2 Warrant.

          (ii) Delivery of Securities. The Company shall have delivered to the Purchaser the
duly executed C-1 Warrant and C-2 Warrant (each in proper form and in such denominations as the
Purchaser shall reasonably request), registered in the Purchaser’s name.

	8.	 	GOVERNING LAW; MISCELLANEOUS.

     (a) Governing Law; Jurisdiction. This Agreement shall be governed by and construed in
accordance with the laws of the State of Delaware applicable to contracts made and to be performed
in the State of Delaware. The Company and the Purchaser irrevocably consent to the jurisdiction of
the United States federal courts and the state courts located in the County of New Castle,
Delaware, in any suit or proceeding based on or arising under this Agreement and irrevocably agree
that all claims in respect of such suit or proceeding may be determined in such courts. The Company
and the Purchaser irrevocably waive the defense of an inconvenient forum to the maintenance of such
suit or proceeding in such forum. The Company and the Purchaser further agree that service of
process upon the Company mailed by first class mail shall be deemed in every respect effective
service of process upon the Company in any such suit or proceeding. Nothing herein shall affect
the right of the Company or any Purchaser to serve process in any other manner permitted by law.
The Company and the Purchaser agree that a final non-appealable judgment in any such suit or
proceeding shall be conclusive and may be enforced in other jurisdictions by suit on such judgment
or in any other lawful manner.

- 26 -

 

     (b) Counterparts. This Agreement may be executed in two or more counterparts, all of
which shall be considered one and the same agreement and shall become effective when counterparts
have been signed by each party and delivered to the other party. This Agreement, once executed by
a party, may be delivered to the other parties hereto by facsimile transmission of a copy of this
Agreement bearing the signature of the party so delivering this Agreement. In the event any
signature is delivered by facsimile transmission, the party using such means of delivery shall
cause the manually executed execution page(s) hereof to be physically delivered to the other party
within five days of the execution hereof, provided that the failure to so deliver any manually
executed execution page shall not affect the validity or enforceability of this Agreement.

     (c) Construction. Whenever the context requires, the gender of any word used in this
Agreement includes the masculine, feminine or neuter, and the number of any word includes the
singular or plural. Unless the context otherwise requires, all references to articles and sections
refer to articles and sections of this Agreement, and all references to schedules are to schedules
attached hereto, each of which is made a part hereof for all purposes. The descriptive headings of
the several articles and sections of this Agreement are inserted for purposes of reference only,
and shall not affect the meaning or construction of any of the provisions hereof.

     (d) Severability. If any provision of this Agreement shall be invalid or
unenforceable in any jurisdiction, such invalidity or unenforceability shall not affect the
validity or enforceability of the remainder of this Agreement or the validity or enforceability of
this Agreement in any other jurisdiction.

     (e) Entire Agreement; Amendments. This Agreement and the other Transaction Documents
(including any schedules and exhibits hereto and thereto) contain the entire understanding of the
Purchaser, the Company, their affiliates and persons acting on their behalf with respect to the
matters covered herein and therein and, except as specifically set forth herein or therein, neither
the Company nor the Purchaser make any representation, warranty, covenant or undertaking with
respect to such matters. No provision of this Agreement may be waived other than by an instrument
in writing signed by the party to be charged with enforcement, and no provision of this Agreement
may be amended other than by an instrument in writing signed by the Company and the Purchaser.

     (f) Notices. Any notices required or permitted to be given under the terms of this
Agreement shall be in writing and sent by certified or registered mail (return receipt requested)
or delivered personally, by nationally recognized overnight carrier or by confirmed facsimile
transmission, and shall be effective five days after being placed in the mail, if mailed, or upon
receipt or refusal of receipt, if delivered personally or by nationally recognized overnight
carrier or confirmed facsimile transmission, in each case addressed to a party as provided herein.
The initial addresses for such communications shall be as follows, and each party shall provide
notice to the other parties of any change in such party’s address:

(i) If to the Company:

Remote Dynamics, Inc.

1155 Kas Drive, Suite 100

- 27 -

 

Richardson, TX 75081

Telephone: (972) 301-2733

Facsimile: (972) 301-2633

Attention: J. Raymond Bilbao, Esquire

with a copy simultaneously transmitted by like means (which transmittal shall not constitute notice hereunder) to:

Locke Liddell & Sapp LLP

2200 Ross Avenue

Suite 2200

Dallas, TX 75201-6776

Telephone: (214) 740-8570

Facsimile: (214) 756-8570

Attention: Stephen L. Sapp, Esquire

(ii) If to any Purchaser, to the address set forth under the Purchaser’s name on the Execution
Page hereto executed by the Purchaser.

     (g) Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties and their successors and assigns. Except as provided herein, the Company
shall not assign this Agreement or any rights or obligations hereunder. Any Purchaser may assign
or transfer the Securities pursuant to the terms of this Agreement and of such Securities, or
assign the Purchaser’s rights hereunder to any other person or entity in accordance with applicable
law.

     (h) Third Party Beneficiaries. This Agreement is intended for the benefit of the
parties hereto and their respective permitted successors and assigns, and is not for the benefit
of, nor may any provision hereof be enforced by, any other person; provided, however, that Section
4(q) may be enforced by any Purchaser’s affiliates and its or their advisors to the extent the same
is entitled to reimbursement of Expenses pursuant thereto.

     (i) Survival. The representations and warranties of the Company and the agreements
and covenants set forth in Sections 3, 4, 5 and 8 hereof shall survive the Closing for a period of
two years notwithstanding any due diligence investigation conducted by or on behalf of any
Purchaser. Moreover, none of the representations and warranties made by the Company herein shall
act as a waiver of any rights or remedies any Purchaser may have under applicable U.S. federal or
state securities laws.

     (j) Publicity. The Company and the Purchaser shall have the right to approve before
issuance any press releases, SEC or, to the extent applicable, NASD filings, or any other public
statements with respect to the transactions contemplated hereby; provided, however, that the
Company shall be entitled, without the prior approval of the Purchaser, to make any press release
or SEC or, to the extent applicable, NASD filings with respect to such transactions as is required
by applicable law and regulations (although the Purchaser shall be consulted by the Company in
connection with any such press release and filing prior to its release and shall be provided with a
copy thereof and must provide specific consent to the use of their name in connection therewith,

- 28 -

 

which consent shall not be withheld if Company counsel advises the Company in writing that
NASD rules or applicable law explicitly require the use of the Purchaser’s name).

     (k) Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other
agreements, certificates, instruments and documents, as the other party may reasonably request in
order to carry out the intent and accomplish the purposes of this Agreement and the consummation of
the transactions contemplated hereby.

     (l) Indemnification. In consideration of the Purchaser’s execution and delivery of
this Agreement and the other Transaction Documents and purchase of the Securities hereunder, and in
addition to all of the Company’s other obligations under this Agreement and the other Transaction
Documents, from and after the Closing, the Company shall defend, protect, indemnify and hold
harmless the Purchaser and each other holder of the Securities and all of their stockholders,
partners, members, officers, directors, employees and direct or indirect investors and any of the
foregoing persons’ agents or other representatives (including, without limitation, those retained
in connection with the transactions contemplated by this Agreement, collectively, the
“Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses,
costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective
of whether any such Indemnitee is a party to the action for which indemnification hereunder is
sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified
Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or relating to (i) any
misrepresentation or breach of any representation or warranty made by the Company in this
Agreement, any other Transaction Document or any other certificate, instrument or document
contemplated hereby or thereby, (ii) any breach of any covenant, agreement or obligation of the
Company contained in this Agreement, any other Transaction Document or any other certificate,
instrument or document contemplated hereby or thereby or (iii) any cause of action, suit, claim,
order, proceeding or process brought or made against such Indemnitee by a third party (including
for these purposes a derivative action brought on behalf of the Company) and arising out of or
resulting from (A) the execution, delivery, performance or enforcement of this Agreement, any other
Transaction Document or any other certificate, instrument or document contemplated hereby or
thereby, (B) any transaction financed or to be financed in whole or in part, directly or
indirectly, with the proceeds of the issuance and sale of the Securities, or (C) the status of the
Purchaser or holder of the Securities as an investor in the Company. To the extent that the
foregoing undertaking by the Company may be unenforceable for any reason, the Company shall make
the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities
which is permissible under applicable law. Except as otherwise set forth herein, the mechanics and
procedures with respect to the rights and obligations under this Section 8(l) shall be the same as
those set forth in Section 6(c) of the Registration Rights Agreement.

     (m) Payment Set Aside. To the extent that the Company makes a payment or payments to
any Purchaser hereunder or pursuant to any of the other Transaction Documents or any Purchaser
enforces or exercises its rights hereunder or thereunder, and such payment or payments or the
proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared
to be fraudulent or preferential, set aside, recovered from, disgorged by or are required to be
refunded, repaid or otherwise restored to the Company, a trustee, receiver or

- 29 -

 

any other person under any law (including, without limitation, any bankruptcy law, state or
federal law, common law or equitable cause of action), then to the extent of any such restoration
the obligation or part thereof originally intended to be satisfied shall be revived and continued
in full force and effect as if such payment had not been made or such enforcement or setoff had not
occurred.

     (n) Joint Participation in Drafting. Each party to this Agreement has participated in
the negotiation and drafting of this Agreement and the other Transaction Documents. As such, the
language used herein and therein shall be deemed to be the language chosen by the parties hereto to
express their mutual intent, and no rule of strict construction will be applied against any party
to this Agreement.

     (o) Remedies. No provision of this Agreement or any other Transaction Document
providing for any remedy to a Purchaser shall limit any other remedy which would otherwise be
available to the Purchaser at law, in equity or otherwise. Nothing in this Agreement or any other
Transaction Document shall limit any rights any Purchaser may have under any applicable federal or
state securities laws with respect to the investment contemplated hereby. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Purchaser by
vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company
acknowledges that the remedy at law for a breach of its obligations hereunder (including, but not
limited to, its obligations pursuant to Section 5 hereof) will be inadequate and agrees, in the
event of a breach or threatened breach by the Company of the provisions of this Agreement
(including, but not limited to, its obligations pursuant to Section 5 hereof), that the Purchaser
shall be entitled, in addition to all other available remedies, to an injunction restraining any
breach and requiring immediate issuance and transfer of the Securities, without the necessity of
showing economic loss and without any bond or other security being required.

     (p) Knowledge. As used in this Agreement, the term “knowledge” of any person or
entity shall mean and include (i) actual knowledge and (ii) that knowledge which a reasonably
prudent business person could have obtained in the management of his or her business affairs after
making due inquiry and exercising due diligence which a prudent business person should have made or
exercised, as applicable, with respect thereto.

[REMAINDER OF PAGE LEFT BLANK INTENTIONALLY]

- 30 -

 

     IN WITNESS WHEREOF, the undersigned Purchaser and the Company have caused this Agreement to be
duly executed as of the date first above written.

REMOTE DYNAMICS, INC.

	 	 	 	 	 
	By:

	 	/s/ W. Michael Smith
	 	 
	 	 	 	 	 
	Name: W. Michael Smith	 	 
	Title: Chief Operating Officer	 	 

PURCHASER:

SDS CAPITAL GROUP SPC, LTD. for itself and on behalf of its Class A Segregated portfolio, Class
B Segregated portfolio, Class C Segregated portfolio and all future Segregated portfolios created
by it from time to time

(Print or Type Name of Purchaser)

	 	 	 	 	 
	By:

	 	/s/ Kevin Johnson
	 	 
	 	 	 	 	 
	Name: Kevin Johnson	 	 
	Title: Managing Director	 	 

RESIDENCE: CAYMAN ISLANDS

	 	 	 
	ADDRESS:

	 	c/o SDS Management, LLC
	 

	 	53 Forest Avenue, Second Floor
	 

	 	Old Greenwich, CT 06870
	 

	 	Telephone: (203) 967-5850
	 

	 	Facsimile: (203) 967-5851
	 

	 	Attention: Steven Derby

[SIGNATURE
PAGE TO SECURITIES PURCHASE AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]